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Polyphenols are known to be major inhibitors of dietary non-haem iron 
bioavailability, mainly through their action as iron chelators. In this present study 
Caco-2 cells were used to investigate the influence of quercetin, the most abundant 
flavonol in the diet, on non-haem iron bioavailability using 
55
Fe, and the gene 
expression of intestinal iron transporters as measured via qPCR. 
 
Chronic exposure to quercetin (24 hours) had no significant effect on iron uptake but 
iron efflux was significantly decreased. Consistent with this, qPCR analysis revealed a 
significant decrease in basolateral transport genes ferroportin (FPN) and hephaestin 
expression suggesting polyphenols may have direct gene regulatory effects. Exploring 
the cellular mechanisms underlying quercetin-induced FPN down-regulation, 
transfection of 5’FPN promoter constructs showed quercetin did not affect activity but 
did decrease FPN1A mRNA whilst increasing FPN1B expression; this suggests that 
although FPN1B is specific to intestinal epithelial cells, FPN1A remains the major 
isoform. FPN 3’UTR miRNA array analysis identified candidate hsa-miR-17-3p to be 
significantly activated by quercetin (1.5 fold) and qPCR validation confirmed up-
regulation of 101 ± 25.1 -fold (p<0.01). This represents a novel mechanism of 
quercetin-induced miRNA-mediated regulation of FPN. 
 
In HepG2 cells quercetin stimulated hepcidin expression and inhibited ferroportin 
gene expression; this may provide an additional means of regulating systemic iron 
levels. Quercetin was shown to be both pro- and anti- proliferative/apoptotic 
dependent on the concentration used which may have beneficial consequences for 
liver pathology of iron-overload diseases. 
 
In contrast to findings in Caco-2 cells, in Thp1 macrophages quercetin caused a 
significant dose-dependent increase in FPN expression. Furthermore, quercetin 
induced both FPN1A and 1B promoter activities. This strongly implies that quercetin 
acts at the level of the FPN promoter to increase FPN expression - an effect specific to 
macrophages only. This demonstrates that quercetin has cell-specific effects and its 
actions on FPN are differentially regulated dependent on cell/tissue type.
 ii 
The results show that quercetin can have multiple effects on iron homeostasis. Given 
its relatively long half-life in the circulation, repeated dietary intake of quercetin could 
lead to plasma accumulation in vivo. This may have important consequences for 
conditions that are low in iron such as anaemia; alternatively it has therapeutic 
potential for iron overload diseases such as haemochromatosis. By deducing the 
mechanisms of how dietary polyphenols interact with our intake of essential nutrients 
such as iron, intake can be optimised to harness the potential benefits polyphenols 
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1.1.  General iron introduction 
 
Iron is one of the most important trace metals required for human life due to its 
fundamental roles in basic cell biology. It is involved in DNA synthesis and electron 
transport in mitochondria as well as being the main component of haemoglobin in red 





) state enables it to take part in many redox reactions in the body. 
Through the Fenton- Haber-Weiss reaction free radicals can be generated, which are 















               Fe
2+
 + O2   Haber-Weiss reaction 
 
However, excess tissue iron can cause oxidative stress, damaging cellular 
macromolecules including protein, DNA and mitochondria leading to cell death and 
tissue injury. There are no physiological means of excreting large amounts of iron thus 
iron homeostasis is primarily regulated at the dietary absorption stage. As both iron 
excess and deficiency can lead to cell damage, the balance of body iron levels must be 
tightly controlled. 
 
1.2. Iron homeostasis 
 
The human body contains approximately 3 - 5 g of iron (45 - 55 mg/kg of body 
weight). 60 – 70% of total body iron can be found in haemoglobin of circulating red 
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blood cells (Andrews 1999a). Iron-rich organs include muscle and liver, which has a 
dual role in iron metabolism of iron storage and hepcidin synthesis which is discussed 
later. A major supply of iron is from macrophages which are responsible for degrading 
haemoglobin from senescent erythrocytes and releasing iron back in to the circulation. 
This demonstrates an efficient cycle of iron re-utilisation, which ensures that only 
small amounts of iron are lost through minor bleeding and mucosal sloughing (Green 
et al. 1968). It is necessary to replace this loss and so although intestinal absorption 
might contribute to a small proportion of body iron, the 1-2 mg/day of dietary iron 











Figure 1.1 Iron distribution 
The duodenum is the main site of dietary iron absorption to replace the iron lost through 
epithelial cell shedding and blood loss. To maintain iron homeostasis requires coordination 
between absorption, utilization and storage sites (Pantopoulos 2004, Papanikolaou and 
Pantopoulos 2005).  
  1. Introduction 
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1.2.1. Iron absorption 
There are two main forms of dietary iron: haem and non haem iron. Non-haem iron is 
found mainly in plant-based foods and accounts for about 90 – 95 % of total daily iron 
intake but its bioavailability is poor (1 - 10 %). Haem-bound iron which is found 
mainly in meats, comprises 5 - 10 % of dietary iron but due to its high bioavailability, 
it contributes to almost half of the daily iron absorption in western diets (Sharp & Srai 
2007).  
 
Dietary iron is predominantly absorbed in the duodenum and upper jejunum although 
the transport pathway for haem and non-haem iron differs across the apical membrane 
of enterocytes. Little is known about the mechanism of haem uptake. Recently, haem 
carrier protein 1 (HCP1) was identified as an intestinal haem transporter (Shayeghi et 
al. 2005) whose expression was regulated by iron deficiency and hypoxia. However, 
this was later demonstrated to mainly function as a proton-coupled folate transporter 
(Qiu et al. 2006). It is thought that once inside the cell, haem is degraded by haem 
oxygenase (HO-1) and the iron released enters a common intracellular pool merging 
with the non-haem iron transport pathway to be processed for subsequent release. 
 
Non-haem iron exists primarily in the insoluble ferric (Fe
3+
) state which must first be 
reduced to ferrous iron (Fe
2+
) for transport across the epithelium. This is accredited to 
duodenal cytochrome B (DcytB), an endogenous ferric reductase found on the apical 
membrane of enterocytes (McKie et al. 2001). Dietary components such as ascorbic 
acid are also thought to contribute to this reduction process (Sharp and Srai 2007). 
Iron is transported across the apical membrane into the cell by divalent metal 
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transporter 1 (DMT1). The acidic environment provides a rich source of protons 
required for DMT1 co-transport of iron as well as other divalent metals such as Cu
2+
 
(Gunshin et al. 1997, Tandy et al. 2000). 
 
Once inside the cell, iron can either be stored as ferritin or transferred to the basal 
transporter ferroportin (FPN) for transport out of the cell and into the circulation 
(McKie et al. 2000). FPN releases ferrous iron which must be re-oxidised to its ferric 
state to be able to bind to circulating transferrin for ongoing transport. This oxidation 
at the basolateral surface is most likely performed by hephaestin (Hp) – a membrane-
bound, copper-dependent ferroxidase (Chen et al. 2004, Vulpe et al. 1999). 
 
  




Figure 1.2 Intestinal non-haem iron absorption 
Dietary non-haem iron is preferentially absorbed in the in the ferrous (Fe
2+
) state. For non-
haem iron this reduction is caused by dietary components e.g. ascorbic acid or endogenously 
by the ferriductase DcytB which is located on the brush border. Iron is transported through the 
apical membrane by DMT1 by a proton coupled mechanism. Inside, iron can bind to ferritin 
for storage, or be transported to the basolateral transporter FPN (ferroportin) for export. Iron is 
oxidised back to Fe
3+
 by hephaestin and bound to transferrin for re-distribution (Zimmermann 
and Hurrell 2007). 
 
1.3. Proteins involved in iron transport 
1.3.1. Duodenal cytochrome B (DcytB) 
DcytB is a 286 amino acid-long ferric reductase located primarily at the intestinal 
brush-border membrane (McKie et al. 2001). Discovered in 2001 by subtractive 
cloning, the process gave way to finding other key regulators of iron metabolism 
including DMT1 and ferroportin. The location and close proximity of DcytB to DMT1 
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suggests its involvement in dietary iron absorption: reducing ferric iron to the more 
accessible ferrous form for DMT1 mediated cellular uptake (Wyman et al. 2008). 
Additionally, there is a quick induction of DcytB gene and protein expression in 
response to iron deficiency and hypoxia further supporting its functional role in iron 
metabolism (McKie et al. 2001). Surprisingly in DcytB knockout mice, there were no 
changes in iron stores and no observable signs of iron-deficiency. This suggests that 
DcytB is not needed for iron absorption in mice and has perhaps other physiological 
roles. However, it can be argued that the roles of DcytB may indeed differ between 
species as mice only express DcytB protein in erythroblasts whereas humans express 
it in many tissues (Su et al. 2006). Also, mice have less need for ferric reductase 
because they are capable of producing large amounts of ascorbic acid for iron 
reduction whereas humans cannot and are reliant on dietary vitamin C (McKie et al. 
2001, Sharp and Srai 2007). 
 
Progress is being made in finding other endogenous ferricreductases and the STEAP 
(six-transmembrane epithelial antigen of the prostate) family of reductases has 
recently been identified for its role in iron uptake in erythroid cells which, as well as 
iron, can also reduce copper (Ohgami et al. 2005).  
 
1.3.2. Divalent metal transporter 1 (DMT1) 
DMT1 is 561 amino acids long and contains 12 transmembrane spanning domains 
(Figure 1.3). It was initially called Nramp2 due its sequence similarity to Nramp1. To 
determine its function, a DMT1 mRNA construct was injected into Xenopus oocytes 
and screened for iron uptake activity (Gunshin et al. 1997). There was a substantial 
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increased uptake of iron compared to control and the name DCT1 (Divalent Cation 















were also shown to be transported (decreasing order of magnitude) (Garrick et al. 
2003). It was also shown that the mechanism of DMT1 transport is proton-dependent, 
and therefore iron uptake is facilitated by the acidic environment of the proximal 
duodenum.  
 
In parallel, its role in iron transport was confirmed, when a DMT1 gene mutation in 
microcytic mice (mk) and Belgrade rats (b) (Fleming et al. 1997, Fleming et al. 1998) 
caused a microcytic, hypochromic anaemia phenotype associated with defective iron 
uptake and gastrointestinal iron absorption. This highlighted DMT1 as a major 
transporter in intestinal iron uptake. Andrews (1999b) suggested the name be changed 
to DMT1 and this is now the most widely used name for this transporter (N. C. 
Andrews 1999b). 
 
DMT1 has at least four different mRNA transcripts produced by alternative splicing at 
both the N-terminal and C-terminal regions (Hubert and Hentze 2002). Two variants 
are produced at the 5’ end from alternative promoters with two different transcription 
sites classified as exon 1A and 1B (Figure 1.3). These are differentially expressed 
where exon 1B is ubiquitous, whereas 1A is tissue-specific with highest expression 
being in the duodenum and kidney (Hubert and Hentze 2002). It has been stipulated 
that these variants have different functional significance and their differing promoters 
also has potential regulatory significance (Garrick et al. 2003). Two further variants 
are created by alternative splicing at the 3’ end either containing an iron response 
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element (IRE) (I) or non-IRE (II). Thus so far, four different isoforms have been 
identified resulting in different exons in mRNA and protein. Interestingly, in human 
intestinal Caco-2 cells it has been shown that variant DMT1B(I) can be regulated by 
iron whereas DMT1B(II) cannot, suggesting further IRE regulatory mechanisms may 
be in play. Moreover, iron has a regulatory effect on DMT1B(I) in mouse kidney cells 
but not in mouse duodenal cells suggesting iron-regulation of DMT1 may also be 
tissue-specific (Hubert and Hentze 2002). 
 
 
Figure 1.3 Model of DMT1 transporter 
DMT1 has 12 transmembrane regions with N- and C- termini facing the cytosol and two 
potential glycosylation sites at the fourth extracellular loop. There are four isoforms: Exons 
1A and 1B are produced by 2 different promoters at the N-terminal, whereas variants in the C-
terminal are produced by alternative splicing with IRE (I) or without-IRE (II) (Yanatori et al. 
2010). 
 
1.3.3. Ferroportin (FPN) 
Ferroportin (FPN) is the only known mammalian iron exporter. A product of the 
SLC40A1 gene, it encodes for a protein 571 amino acids in length with a predicted 
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mass of 62 kDa. FPN was discovered by three independent groups, by three different 
methods, each of whom gave it a different name, thus it can be called metal 
transporter 1 (MTP1), iron-regulated protein 1 (IREG1) and ferroportin-1 (FPN1) 
respectively (Abboud and Haile 2000, McKie et al. 2000, Donovan et al. 2000). Its 
importance in iron homeostasis has been well documented. In cell culture models, 
over-expression of FPN caused intracellular iron depletion and tissue-specific activity 
was demonstrated by iron deficiency upregulating FPN expression in mouse 
duodenum but down-regulating expression in liver (Abboud and Haile 2000). Using 
Xenopus oocytes, FPN was shown to function as an iron exporter, stimulating iron 
efflux at the basolateral surface of polarised epithelial cells, capable of exporting 
cellular iron into the circulation (Donovan et al. 2000, McKie et al. 2000). Insight was 
given into the FPN structure when it was shown that the 5’UTR of FPN contained a 
functional IRE. However, in iron deficient conditions, this IRE would cause 
translation repression after IRP binding whereas FPN mRNA and protein increased in 
such conditions, making it unclear whether the IRE/IRP complex affects translation or 
stability of FPN (McKie et al. 2000). 
 
FPN has more than 90% homology between humans, mice and rats, making it a highly 
conserved protein inter-species. This conservation suggests FPN has a fundamental 
role in iron homeostasis. FPN is the only known iron exporter in vertebrates. 
Complete inactivation of FPN in mice and zebrafish caused embryonic lethality 
indicating its essential role in early development (Donovan et al. 2005). Mice that 
were FPN-deficient after birth showed iron accumulation in enterocytes, hepatocytes 
and macrophages, stressing a key role of FPN for iron release within these cell types. 
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Intestine-specific inactivation caused duodenal iron accumulation in this tissue only, 
confirming that it is critical for iron absorption (Donovan et al. 2005). This highlights 
FPN as one of the most important proteins in iron homeostasis. 
 
However there is still a lot unknown about FPN. Little work has been carried out on 
the FPN structure to identify how it carries out transmembrane iron transport and there 
is no general consensus on its topology.  Earlier studies proposed it to have ten 
transmembrane domains (Donovan et al. 2000, McKie et al. 2000) but more recent 
topology software has predicted 12 transmembrane domains (Liu et al. 2005). The 
positions of N- and C- termini are also under debate with some suggesting both 
termini to be intracellular (Liu et al. 2005) whilst others depicting an intracellular N- 
terminal and an extracellular C- terminal (Devalia et al. 2002). Another structural 
controversy is whether FPN is a monomer or a multimer. Coimmunoprecipitation of 
FPN with different epitope tags and detection of FPN with a larger mass than the 
monomer, indicate that FPN functions as a multimer (De Domenico et al. 2005). 
However in similar epitope-tagged studies, there was a lack of coimmunoprecipitation 
and co-localisation of mutant with wild-type FPN arguing against FPN hetero-
oligomers and in vivo studies suggested FPN as a monomer (Goncalves et al. 2006, 
Schimanski et al. 2005, Schimanski et al. 2008). A more recent study has shown that 
FPN is a monomer. Using multiple techniques including size exclusion 
chromatography and UV absorption spectroscopy analysis, purified, detergent-
solubilized human FPN was observed as a single peak. Furthermore, SDS-PAGE 
analysis revealed a single predominant band with a molecular mass of approximately 
60 kDa in agreement with its predicted weight (Rice et al. 2009). Although it was 
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noted that a transient dimerisation/multimerisation event could not be completely 
ruled out. Expression of FPN was observed at the basolateral membrane of polarised 
epithelial cells but not at the apical surface. To address the issue of N-/C- termini 
location, confocal microscopy utilising fluorescent antibodies, strongly supported 
cytosolic location for both termini and a 12 transmembrane domain topology similar 
to (Liu et al. 2005) was suggested (Rice et al. 2009).   
 
The 5’UTR of FPN mRNA contains a putative IRE that could indicate translational 
regulation by iron regulatory proteins (IRPs) in a similar way to other IRE-regulated 
genes (e.g. ferritin) (Cianetti et al. 2010). Experiments with luciferase reporter gene 
assays have shown that this 5’IRE was responsive to iron in HepG2 (hepatocyte), 
Caco-2 (enterocyte) and U937 (macrophage) cells (Lymboussaki et al. 2003). 
Recently a variant of FPN, FPN1B, has been identified which lacks the IRE by using 
an alternative upstream promoter allowing it to evade the IRE/IRP system (Zhang et 
al. 2009) thus it could possibly undergo post-translational regulation instead. FPN1B 
is more specific to duodenal epithelial and erythroid precursor cells suggesting a 
tissue-specific regulatory mechanism. Iron regulation of FPN appears to be highly 
complex with many levels of possible regulation, both transcriptional and post-
transcriptional but as the only known significant iron exporter in tissues involved in 
iron absorption, storage and recycling, its role in iron homeostasis is clearly 
indispensable.   
  
































Figure 1.4 Predicted models of FPN transporter 
Topology of FPN protein, modified from two alternative models. (A) 9 transmembrane helices 
proposed by (Devalia et al. 2002). (B) 12 transmembrane helices by (Liu et al. 2005). Adapted 
from (Wessling-Resnick 2006). Black filled circles represent known possible human 
mutations. N- and C-termini denoted by N and C respectively. Top of each diagram represents 








Hephaestin is a multi-copper oxidase required for basolateral oxidization of iron from 
enterocytes, to allow iron binding to circulating transferrin and is therefore 
categorized as a ferroxidase (Vulpe et al. 1999). Encoded by the HEPH gene, the 
product is a transmembrane-bound protein, which is 50% identical at the protein level 
to serum oxidase ceruloplasmin. Both contain iron and copper binding sites but where 
their function may be similar, their location is not. Ceruloplasmin is expressed mainly 
in liver and is plasma-soluble whereas hephaestin is highly expressed in the intestine 
and anchored to the plasma membrane (Chen et al. 2004, Vulpe et al. 1999).  
 
A spontaneous mutation in HEPH has been observed in sex-linked anaemia (sla) mice 
through gene-mapping studies. A deletion of 582 bases in the mRNA of the gene 
produces a shortened protein missing 194 amino acids. This mutation results in a 
failure of hephaestin to localise to the basolateral membrane of the intestine, causing 
functional defects (Kuo et al. 2004). Mice exhibit intestinal iron accumulation and 
systemic iron deficiency suggesting the important role of hephaestin in basolateral 
iron export (Chen et al. 2004, Vulpe et al. 1999). 
 
Unlike the other proteins of iron transport, hephaestin expression does not appear to 
be significantly affected by local cellular iron levels (Chen et al. 2003). However, 
hephaestin mRNA was increased in the duodenum of iron-deficient mice thereby 
possibly suggesting that hephaestin expression is more responsive to systemic iron 
levels than that of iron levels in enterocytes (Chen et al. 2003). It is also important to 
remember that hephaestin requires copper for structural stability and enzymatic 
activity and therefore levels of copper affect hephaestin expression. Indeed hephaestin 
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protein and ferroxidase activity have been shown to decrease in copper-deficient mice 
and rats respectively (Chen et al. 2006, Reeves et al. 2005) confirming that copper is 
required for the proper synthesis and functioning of hephaestin.  
 
1.3.5. Ferritin 
Ferritin is the primary iron storage protein found ubiquitously in tissues. Ferritin is a 
450 kDa protein comprising of 24 apoferritin monomers that come together to form a 
hollow spherical particle (Harrison and Arosio 1996) (Figure 1.5). This sphere is 
capable of binding up to 4500 ferric atoms, making it a very effective iron delivery 
system (Wang et al. 2010). The ferritin molecule consists of different ratios of two 
subunits termed L (light) and H (heavy). H refers to the fact it is the heavier of the two 
subunits weighing 21 kDa or to its original isolation from the human heart, which is 
rich in the H subunit. L is the lighter subunit weighing 19 kDa and is the predominant 
form in liver (Wang et al. 2010, Torti and Torti 2002). Most tissue ferritins are a 
mixture of the subunits, with the ratio depending on tissue type, developmental stage, 
inflammatory condition, amongst other stimuli (Torti and Torti 2002). H subunit has 
enzymatic ferroxidase activity which allows internalisation and sequestration of iron 
in the ferritin core (Lawson et al. 1989).  
 
Ferritin can be regulated post-transcriptionally by the IRE/IRP system which responds 
to intracellular iron levels. A more in-depth discussion of the IRE/IRP system can be 
found in the next section (1.4.1). Ferritin mRNA contains IRE in its 5’UTR (Hentze et 
al. 1987), which bind IRPs when iron is low, inhibiting translation so less of the 
protein is synthesized when it is not required (Torti and Torti 2002). 













Figure 1.5 Tertiary structure of ferritin multimer 
Iron storage protein ferritin consists of 24 monomers  of heavy and light subunits to form a 
central spherical cage which can hold up to 4500 ferric atoms in a non-toxic form (Marchetti 
et al. 2009). 
 
 
1.4. Regulation of iron homeostasis 
1.4.1. Cellular control: IRE/IRP system 
Cellular iron levels are maintained by coordinating iron uptake, utilisation and 
storage. It is thought that the main regulation of cellular iron levels occurs post-
transcriptionally to allow for quicker changes in protein expression by changing the 
rate of mRNA synthesis. In iron metabolism, this involves iron-response element 
(IRE) / iron regulatory protein (IRP) interaction. 
 
IREs are conserved hairpin structures of 25 – 30 base pairs that are located on 3’- or 
5’- UTR (untranslated regions) of mRNA that encode for proteins of iron metabolism. 
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The cellular liable iron pool regulates binding of IRP1 and IRP2 to these elements to 
optimise iron availability.  
 
IRP1 is an iron-cluster containing protein which has a dual function alternating 
between an IRP and an active cytosolic aconitase. During normal or high iron levels, 
IRP1 has a 4Fe-4S cluster ligated to its active site preventing it from binding to IRE 
and functions as an aconitase. However, when iron levels are low, the iron-sulphur 
cluster dissembles and IRP1 assumes an open configuration that can bind to the IRE 
hairpin structure. Conversely IRP2 is produced de novo during iron depletion but 
targeted for rapidly degradation in iron-replete cells (Iwai et al. 1998).  
 
The location of IRE results in differential effects. IRPs binding to 5’-IRE prevent 
ribosomal binding to target mRNA thereby inhibiting translation. Whereas IRPs 
binding to 3’-IRE prevent endonuclease degradation resulting in mRNA stabilisation 
and increased protein production (Binder et al. 1994).  
 
DMT1 and transferrin receptor 1 (TfR1) mRNA both have IREs at the 3’UTR (DMT1 
has a single IRE while TfR1 has five IREs) whereas FPN and ferritin have an IRE at 
the 5’-UTR. Therefore in low iron conditions, IRPs stabilise DMT1 mRNA increasing 
protein synthesis to promote cellular iron import; FPN and ferritin translation are 
repressed. Conversely, in high iron conditions, FPN and ferritin translation proceeds 
for export and storage of excess iron respectively and DMT1 mRNA is destabilised to 
stop further cellular uptake of iron (Torti and Torti 2002). 
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IRP2 is a slightly larger protein than IRP1 (105 kDa and 87 kDa respectively) due to 
an extra 73 amino acids but despite being 60 – 70% homologous with IRP1, IRP2 
does not possess any aconitase activity and its primary function appears to be 
controlling translation of IRE-containing mRNAs. There is also some tissue 
specificity as IRP1 activity in rodents is abundant in liver, intestine and kidney, while 
IRP2 has highest activity in intestine and brain (Henderson et al. 1993). IRP2 appears 
to be the better iron sensor as it is able to complement IRP1 function in IRP1 
knockout mice which did not show any overt signs of abnormality (LaVaute et al. 
2001). IRP2 knockout mice, however, exhibited misregulated iron metabolism in the 
intestinal mucosa and the central nervous system suggesting that IRP2 is more 
important in regulating iron metabolism as IRP1 cannot compensate for the loss of 
function. Knockout of both IRP1 and IRP2 caused embryonic lethality (Smith et al. 
2006) demonstrating that the IRE/IRP system is essential for life.  
 
The IRE/IRP system regulates a number of iron-metabolism proteins which allows for 

























Figure 1.6 IRE/IRP regulation of ferritin and TfR 
Low iron causes binding of IRP1 and IRP2 to IRE in ferritin 5’-UTR resulting in repressed 
ferritin translation. However, if the IRE is in 3’-UTR like TfR, then IRP binding stabilizes 
mRNA and increases translation. During high levels of iron, IRP1 is converted to aconitase 
with no IRP activity and IRP2 is rapidly degraded resulting in increased translation of ferrtin 
for iron storage whilst less TfR is synthesized. IRP: iron regulatory protein 1; IRP2: iron 
regulatory protein 2; IRE: iron responsive element; TfR: transferrin receptor (Torti and Torti 
2002).  
 
1.4.2. Systemic control: Hepcidin 
The discovery of hepcidin and its connection to iron came about in many ways. A 
novel antimicrobial peptide, highly expressed in the liver, was isolated by Krause 
(Krause et al. 2000) and named LEAP-1 (liver expressed antimicrobial peptide). 
Around the same time, (Park et al. 2001) isolated the same peptide from human urine 
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and named it hepcidin (hepatic origin and it being a bactericidal protein). In humans, 
hepcidin in encoded by the HAMP gene synthesizing an 84 amino acid protein known 
as a preprohepcidin. This is cleaved to prohepcidin which is 60 amino and further 
processed to give the bioactive mature 25 amino acids hepcidin. Low levels of shorter 
hepcidin peptides (20 and 22 amino acids) can also be detected but they possess little 
activity and are likely to be the degradation products of the mature form (Nemeth et 
al. 2006).  
 
A lot of the information we know about hepcidin comes from in vitro studies and 
mouse models. The role of hepcidin in iron metabolism was first established in 
hepcidin gene-knockout mice which developed severe iron overload with iron 
depositions in liver, pancreas and heart (Nicolas et al. 2001). Conversely, mice over-
expressing hepcidin were born with severe iron deficiency and died soon after birth 
(Nicolas et al. 2002). In adult rats switched from an iron-replete diet to an iron-
deficient diet, hepcidin expression was shown to inversely correlate with iron 
absorption and duodenal iron transporters (Frazer et al. 2002). These finding are all 
consistent with hepcidin acting as a negative regulator of iron absorption. This key 
connection was underlined in humans when it was discovered that patients with 
juvenile haemochromatosis had inactivating hepcidin mutations causing severe iron 
overload (Roetto et al. 2003) confirming the importance of hepcidin in iron 
homeostasis.  
 
The only known molecular target for hepcidin is FPN (Nemeth et al. 2004b). FPN is 
the only known exporter responsible for exporting iron from intestinal enterocytes, 
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macrophages, hepatocytes and placenta to the circulation. Hepcidin acts by directly 
binding to FPN, causing its internalisation and subsequent degradation in lysosomes 
(Nemeth et al. 2004b). This loss of FPN from cell surfaces prevents cellular iron 
export which creates a negative feedback cycle to inhibit further hepcidin release. 
Therefore when iron levels are high, hepcidin is produced by the liver and targets FPN 
on the basolateral membrane of enterocytes to block release of dietary iron to 
transferrin thus reducing plasma iron levels. In macrophages, degradation of FPN 
causes iron trapping characteristic of iron-containing macrophages in inflammation 
when circulating levels of hepcidin are high (Nemeth and Ganz 2006). When iron 
returns to normal levels (or low), hepcidin production is inhibited, allowing FPN re-
synthesis and iron transport and recycling to resume (Figure 1.7). 
 
FPN1B (-IRE) is the more abundant isoform in the intestine and since it is not 
regulated by the IRE/IRP system, it is more likely that FPN1B is regulated at a post-
translational level by hepcidin. Hepcidin may also indirectly affect the IRE/IRP 
system. By inhibiting iron efflux, intracellular iron content is increased which may 
affect the expression of iron importer DMT1+IRE, transferrin and possibly other 
pathways. However this interaction of hepcidin-FPN with the IRE/IRP system is not 
well understood and yet to be confirmed (Nemeth and Ganz 2006).   




Figure 1.7 Regulatory functions of hepcidin 
Reduced plasma hepcidin levels, as a result of reduced body iron stores promotes dietary iron 
absorption in the small intestine and increased iron release from macrophages. An increase in 
hepcidin levels stimulated by high body iron or inflammation inhibits dietary iron absorption 
and iron release from macrophages (Redrawn from Papanikolaou and Pantopoulos 2005). 
 
1.4.3. Other regulators of iron: inflammation; erythropoiesis; hypoxia 
An increase of iron causes increased hepcidin production but the mechanism by which 
this occurs is not known. Hepcidin is produced by the liver but it is not clear if this is 
where iron levels are sensed. Iron loading of primary human and mouse hepatocytes in 
vitro does not affect hepcidin mRNA suggesting that other cell types may be needed 
for iron sensing (Pigeon et al. 2001, Nemeth et al. 2003). The HAMP gene encoding 
for hepcidin does not contain any IRE ruling out IRP binding as a regulatory 
mechanism and suggests iron regulation of hepcidin by other signalling pathways 
instead. Patients with hereditary haemochromatosis (HH) suffer from iron overload 
due to defective hepcidin regulation. In both patients and mice models of the disease, 
mutations have been found in HFE (haemochromatosis protein), transferrin receptor 2 
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(TfR2), and hemojuvelin (HJV), strongly suggesting that these proteins have a role in 
iron regulation of hepcidin (Bridle et al. 2003, Kawabata et al. 2005, Niederkofler et 
al. 2005, Pissia et al. 2004). If and how these pathways interact to regulate hepcidin 
remains elusive.  
 
During infection and inflammation, hepcidin levels are increased. This is a host-
defence mechanism aiming to reduce available iron to invading organisms. This effect 
is mediated by inflammatory cytokines, namely interleukin-6 (IL-6). Healthy human 
volunteers that were infused with recombinant human IL-6 showed a rapid increase in 
hepcidin expression (as measured by urinary excretion) matched with a significant 
decrease of serum iron and transferrin saturation. IL-6 KO-mice failed to produce 
hepcidin mRNA in response to turpentine-induced inflammation (Nemeth et al. 
2004a). These parallel results show that IL-6 is an important regulator of hepcidin 
during inflammation. Recently other cytokines have also been indicated to play a role 
but findings have been controversial. In mice with targeted IL-6 gene disruption (IL-
6-/-) IL-1α and IL-1β were both shown to be potent hepcidin inducers (Lee et al. 
2005) but no affect was observed in primary human hepatocytes (Nemeth et al. 2003). 
In primary rat hepatocytes TNFα exhibited stimulative effects on hepcidin mRNA 
expression (Dzikaite et al. 2006) whereas it had a suppressive hepcidin effect in 
human hepatocytes in vitro (Nemeth et al. 2004a). This suggests that there may be 
variations in the effects of inflammatory cytokines between species (Nemeth and 
Ganz 2006).  
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Erythropoiesis is a hepcidin suppressor, capable of overriding systemic iron status 
(Figure 1.8). During anaemia or hypoxia, the body responds by producing the protein 
erythropoietin (Epo) from the kidneys to stimulate erythroid differentiation at the bone 
marrow. This process decreases hepcidin levels which allow more dietary iron to be 












Figure 1.8 Simplified schematic of Epo signalling 
Binding of Epo to two adjoining receptors leads to their homodimerization and 
phosphorylation of JAK2. This in turn phosphorylates tyrosine residues on the cytoplasmatic 
tail of Epo-R producing docking sites for various downstream signalling molecules such as 
PI3K, STAT5 and MAPK. These molecules eventually migrate to the nucleus to increase 
target gene expression. (Adapted and redrawn from Marzo et al. 2008). 
 
 
The exact mechanism of how Epo regulates hepcidin is not clear. Hepatocytes express 
Epo receptors (Epo-R). Through in vitro work in HepG2 human hepatocyte cell line, it 
has been proposed that Epo binds directly to hepatic Epo-R decreasing transcriptional 
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factor C/EBPα (CCAAT/enhancer binding protein α) binding to the hepcidin 
promoter, thereby suppressing hepcidin expression (Pinto et al. 2008). However 
studies in mice suggest that Epo suppression of hepcidin is caused by downregulation 
of STAT3 and SMAD phosphorylation (Huang et al. 2009) whilst other studies 
suggest the effect of Epo is mainly indirect and an intermediary bone marrow 
response is required (Zhang and Enns 2009). It is not yet clear which aspect has most 
influence on Epo regulation of hepcidin.  
 
Hypoxia is a physiological stimulus of eythropoiesis and hypoxia inducible factors 
(HIFs) play an important role in this process. HIFs are transcription factors comprised 
of two subunits: an oxygen sensitive α subunit (HIF1α/HIF2α) and a constitutively 
expressed β subunit. Although HIF1 and HIF2 share many common targets, they also 
have separate physiological functions and HIF2 appears to regulate Epo production in 
adult life. In normoxic conditions HIF1α is modified by prolyl hydroxlases (PHDs) 
and is subjected to proteosomal degradation. During hypoxia however, PHD activity 
is inhibited, allowing HIF1α accumulation and translocation to the nucleus whereupon 
it dimerises with the β subunit and binds to hepcidin promoter suppressing hepcidin 
expression (Patnaik and Tefferi 2009, Peyssonnaux et al. 2007). This increases iron 
uptake to meet erythropoietic demands. Human hepcidin promoter contains several 
HIF binding sites but their exact role has not been tested so whether HIF binds 
directly to the hepcidin promoter to inhibit its activity remains controversial.  
 
Thalassemia patients display low levels of hepcidin even with systemic iron overload 
indicating that signals for hepcidin suppression dominate over signals of systemic iron 
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and that Epo signaling may be the most potent inhibitor of hepcidin expression 
(Papanikolaou et al. 2005). Interestingly, pro-inflammatory cytokine IL-6 failed to 
induce hepcidin activation in the presence of HIF stabalisation (Peyssonnaux et al. 
2007). This demonstrates a link between inflammation, hypoxia and erythropoiesis 
although the precise mechanism by which they down-regulate hepcidin has yet to be 
defined.  
 
1.4.4. Dietary influence on non-haem iron bioavailability 
Haem  iron absorption is relatively unchanged by meal compositions. However, 
absorption of non-haem iron, which is the more abundant form, can be substantially 
altered by co-consumption of certain dietary factors ( 
 
Figure 1.9). Vitamin C is a powerful enhancer of non-haem iron absorption; the 




, which is the 
form taken up by mucosal cells (Plug et al. 1984) as stomach contents enter the 
duodenum. There are many studies showing a clear dose-dependent effect of vitamin 
C increasing non-haem iron absorption further supporting its promoter activity 
(review of 24 studies by (Bendich and Cohen 1990). 
 
 
Polyphenols are among the most significant dietary inhibitors of non-haem iron 
absorption. Their widespread distribution in food means they are likely to be present 
in most meals and allow interaction with dietary intake of iron. Polyphenols are 
known to be effective iron chelators (Afanas'ev et al. 1989) which is one of the ways 
they may affect non-haem iron bioavailability.  











































Polyphenols are a complex group of chemical molecules derived from plants. Found 
naturally in fruits, vegetables and flowers, the beneficial health effects of plants were 
known long before polyphenols and in particular, flavonoids, were isolated as the 
effective compound.   
 
The Hungarian scientist Albert Szent-Gyorgyi was the first to identify the structure of 
ascorbic acid (commonly known as vitamin C) and its isolation resulted in the 
treatment of scurvy (caused by vitamin C deficiency). A fellow colleague had a 
patient suffering from subcutaneous capillary bleedings and it was suggested that 
vitamin C might help but as sufficient amounts were not yet available, an impure 
substance containing a mixture of vitamin C plus other compounds, was given and 
achieved rapid success. When pure vitamin C was later tested on its own, the same 
results could not be obtained. This suggested to Szent-Gyorgyi that another compound 
must be contributing to the therapeutic effect and going back to the impure substance, 
he suspected a group of plant-based compound with polyphenol structure as a key 
factor.  Based on his experience with vitamin C and his earlier observation that the 
therapeutic effects of a mixed substance was more beneficial than vitamin C alone, he 
suggested that these polyphenols might interact with vitamin C to repair damaged 
tissues by increasing resistance and maintaining integrity of capillary walls. Due to 
some of the compounds possessing vitamin-like properties, he called the polyphenols 
‘vitamin P’ (Szent-Györgyi 1937). This name was later dropped as there was not 
substantial evidence to show that polyphenols were essential like vitamins. Szent-
Gyorgyi proposed that polyphenols possess great biological activity and had the 
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potential of being effective therapeutic agents for a range of diseases. His work on 
vitamin C and ‘vitamin P’ was recognized in 1937 earning him a Nobel Prize in 
Medicine. Szent-Gyorgyi had said flavonoids “represent one of the most exciting, 
broad, and hopeful fields of biological inquiry” (Gabor 1988) and indeed this has 
inspired decades of investigative research in to polyphenols.  
 
Polyphenols are essential for plant physiology, contributing to growth, morphology 
and protection as anti-feedants (unpalatable to predatory animals). Many polyphenols 
act as dyes, responsible for giving flowers their attractive colour and thus can also 
affect pollination by affecting insect feeding (Hedin and Waage 1986). Polyphenol 
structure can vary greatly and further sub-classing depends on the carbon skeleton. Of 
plant polyphenols, flavonoids represent the most widely distributed group but with 
over 6000 members (Harborne and Williams 2000), most experiments in the field 
focus on a much smaller number which are relevant from a dietary viewpoint.  
 
1.6. Flavonoids  
 
Flavonoids are low-molecular-weight polyphenol substances generally composed of a 
three-ring structure (Figure 1.10). They are formed from combining derivatives of 
shikimic acid pathway and acetic acid (reviewed by (Aherne and O'Brien 2002). The 
basic flavonoid structure contains 2 benzene rings (A and B), joined by an oxygen-
containing pyrene ring (C). Variations in ring C and the substitution patterns available 
for rings A and B allow a variety of subgroups to exist. Classification depends on the 
extent of oxidation of the C ring. Their biological properties depend on their chemical 
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structure and degree of modification by additional moieties. Flavonoids are mostly 
present as glycosides, that is they have sugar moieties attached which increases their 
polarity, and lacking this, they are called aglycone. Common sugars are D-glucose and 
L-rhamnose with the preferred site of glycosylation being the C-3 and C-7 positions.  
 
Flavonoids are present in most edible fruits and vegetables, but the type of plants they 
are found in has variations in different flavonoid content. Flavanols can be found in 
cocoa and related products; flavanones in citrus foods; flavones in green leafy spices 
such as parsley and capsicum pepper; isoflavones are found in soy foods, 
anthocyanidins in berries, and flavonols are found in almost all foods (Lakhanpal and 










Figure 1.10 Basic structure and numbering system of flavonoids 
 
Of the flavonoids, flavonols are the most common compounds, present in almost all 
plants. Quercetin is the main flavonol present in our diet. Its dietary abundance, along 
with its interesting chemical and biological properties, has made quercetin one of the 
most extensively studied flavonoids. 



























Figure 1.11 Major classes of food flavonoids 
The structural classification of a flavonoid is based on the degree of hydroxylation of 
the C-ring. Adapted from Aherne and O'Brien 2002. 
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Figure 1.12 Structure of quercetin 
Belonging to the flavonol subclass, 
quercetin is one of the most abundant 
flavonoids in the diet.  
 
Figure 1.13 Structure of rutin 
(quercetin-3-O-rutinoside). 
Quercetin is present in many 
different glycosidic forms with 
rutin being one of the more 
common forms found (Erlund 
2004). The 3-OH group appears to 
be a favoured glycosylation site. 
Quercetin is the predominant dietary flavonoid. In plants it occurs mostly in the 
glysosidic form where glycosylation can occur at any of the hydroxyl group to yield a 
sugar. Common sugars include glucose, galactose and rutinose which bind to aglycone 
quercetin at the 3-poistion (3-O-glycoside) to form rutin (Figure 1.13). The major 
glycosilation targets of quercetin appear to be the 3-, 7- and 4’-hydroxyl groups (Rice-
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Flavonoids are provided by the diet and to understand their biological effects, reliable 
data on flavonoid content within foods is needed. Substantial effort has been made in 
this regard, with the development of analytical methods such as the highly sensitive 
and selective high performance liquid chromatography (HPLC) being the method of 
choice. In a study by Hertog et al. (1992) five flavonoids were quantified in various 
commonly consumed fruits and vegetables. Flavonoid-glycosides were extracted and 
hydrolysed to their aglycone form, then separated and quantified by HPLC and UV 
detection. Table 1.1 shows quercetin content in a number of foods.  Using this 
method, the United States Department of Agriculture has since composed a more 
extensive list of quercetin content in foodstuff.  
 










Onion 340–347 Apple 20–36 Black tea 14–17 
Kale 110–120 Black grape 15–37 Green tea 13-24 
Cherry tomato 63 White grape 2–12 Tomato juice 13 
Broccoli 30–37 Cherry 10–15 Red wine 8.3 
Lettuce 14–79 Plum 9–15     
    Strawberry 6–8.6     
 
Queretin content as measured by HPLC methods after hydrolysis of glycosides. Only edible 
portions were used where appropriate (Hertog et al. 1992, Hertog et al. 1993, Hollman and 
Arts 2000). 
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1.6.1. Dietary intake 
Currently there is no accurate information available on dietary intake of polyphenols, 
only estimations. This is because there is high variability in the types of food consumed, 
individual eating habits and processing of food affecting polyphenol content.  Therefore 
quercetin sources differ greatly between and even within countries. In the Seven 
Countries Study, which started in the 1960s, Hertog et al calculated flavonol intakes 
from different populations and reported that tea was the predominant source of 
quercetin in Dutch and Japanese diets. Red wine was the greatest source of quercetin 
in Italy, whilst in the United States, Finland, and Greece, onions and apples were the 
main source (Hertog et al. 1995). Although onions may not be consumed in high 
amounts, they form a considerable amount of flavonoid intake because of their high 
quercetin content. In contrast, tea and wine contain lower amounts of quercetin but in 
some countries, they are consumed at rather high quantities (Erlund 2004).  
 
The average daily flavonol intake was estimated to be 15 – 30 mg/day for Denmark, 
and similar amounts for Holland and Japan. Finland had the lowest intake of 4 mg/d. 
However cultural diets often dictate which foods are consumed and so which 
flavonoids are most ingested. Japan may have had similar flavonol intake as European 
countries, but soy and soy foods are frequently consumed in Japanese diets and 
consequently they have the highest total flavonoid intake (63 mg/d), with isoflavones 
being the dominant flavonoid in their diet (Hertog et al. 1993b, Hertog et al. 1995, 
Beecher 2003). Cultural habits may remain a strong factor even after migration to a 
new country as East Asians in the US still have a relatively modest intake of 
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isoflavones compared with residents of Japan and non-Asian residents of the US 
(Beecher 2003).  
 
In the United States, the estimated daily intake of flavonols is 20 - 22 mg, of which 
approximately 75% is quercetin (Sampson et al. 2002). Although this is in line with 
the Dutch diet, earlier estimations had been closer to a daily intake of 1 g/d in the US 
(Kuhnau 1976). This has since been stated as an over-estimation, most likely due to a 
lack of reliable analytical methods available at the time. But considering the vast 
number of flavonoids that exist in the diet, and that most studies base intake on only a 
very few select flavonoids, actual flavonoid intake is likely to be higher and perhaps 
levels close to 1 g/d are not completely unreasonable.  
 
Food processing can affect quercetin concentrations. For example boiling foods like 
tomatoes or broccoli greatly reduces the flavonol content. This could be due to heat 
degrading the chemical structure or the polarity of quercetin causing it to leach into 
water. Onions, however, contain quercetin conjugates that lend it stability up to 
temperatures of 100 
o
C. Skins of fruits and leaves of vegetables are where quercetin is 
usually most concentrated so peeling or removing these will cause obvious losses in 
quercetin (Aherne and O'Brien 2002). 
 
Daily polyphenol intake cannot be accurately assessed yet. However, with more 
extensive food composition databases being developed by each county, the precision 
of consumption data for various populations is also surely to improve.  
 




Plasma concentrations of quercetin tend to be in the nanomolar range with 50 - 80 nM 
being the average detected in overnight fasting humans volunteers (Erlund et al. 
2002). However the baseline readings have the potential to increase into  micromolar 
ranges with plasma levels reaching 1.5 µM after 28 days supplementation of a high 
quercetin dose (1 g/d) (Conquer et al. 1998) and 0.63 µM in another study where 
supplementation equivalent of 80 mg/d quercetin was given for 1 week (Kawabata et 
al. 2005). Reviews of bioavailability studies have reported that elimination of 
quercetin and its metabolites are relatively slow, with half lives of 11 – 28 hours 
which suggests it is possible for plasma accumulation to occur with repeated intakes 
(Manach et al. 2005). 
 
Differences in individual gut physiology, including genetics (activity of 
transporters/enzymes) and microflora compositions can affect quercetin metabolism 
and absorption. This makes it difficult to predict bioavailability.  
 
The hydrophobic nature of flavonoid aglycones mean that they can be transported 
directly across cell membrane of enterocytes by passive diffusion but studies have 
shown that the extent of absorption depends on the source of quercetin. Human 
ileostomy volunteers supplemented with various forms of quercetin showed absorption 
(oral intake - ileostomy excretion) of quercetin aglycone was approximately 52% from 
fried onions (contain quercetin-4’-glucoside and quercetin-3,4’-diglucoside), 24% from 
pure quercetin aglycone and 17% from rutin (quercetin-3-O-rutinoside) (Hollman et al. 
1995). Furthermore, in another study, it was demonstrated that the sugar moiety itself has 
a major role in determining absorption (Hollman et al. 1999). The bioavailability of 
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quercetin-rutinoside was only 20% of that of quercetin-glucoside suggesting that 
conjugation to a simple monosaccharide like glucose allows the molecule to be absorbed 
in the small intestine whereas conjugation to a more complex sugar like the disaccharide 
rutinose requires further metabolism in the colon before it can be absorbed. Cell culture 
work implicated the sodium-glucose transporter-1 (SGLT-1) to be involved in the uptake 
of quercetin-glucosides. Using fluorescent microscopy and HPLC analysis, intestinal cell 
line Caco-2 and SGLT1 stable transfected chinese hamster ovary cells (G6D3) showed 
that quercetin-4’-beta-glucoside was actively transported by SGLT1 across the apical 
membrane of enterocytes (Walgren et al. 2000). This was corroborated in rat jejunal tissue 
using quercetin-3-glucoside which demonstrated a clear role of SGLT-1 for its mucosal 
uptake (Wolffram et al. 2002). Other transporters have also been implicated including 
glucose transporter 2 (GLUT2) (Wolffram et al. 2002) and multidrug resistance protein 2 
(MRP2) (Walgren et al. 2000). 
 
Quercetin glycosides that have not been absorbed by the small intestine pass into the 
large intestine where they are hydrolysed by colonic microflora liberating the 
aglycone. This has been suggested to take place in the lower ileum and the cecum 
which contain bacteria that produce β-glucosidases, α-rhamnosidases, and β-
galactosidases enzymes capable of degrading flavonoid-glycosides (Bokkenheuser et 
al. 1987). Thereafter, the aglycone and its degradation products can be absorbed into 
the blood stream and transported to the liver by the portal vein or excreted in faeces. 
The liver is the main organ for flavonoid metabolism and it is here that quercetin is 
methylated and/or conjugated with glucuronic acid or sulphate. After hepatic 
processing quercetin conjugates can be excreted in urine or bile. Those in bile are 
metabolised by intestinal bacteria, hydrolysing glucuronic or sulphate conjugates 
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(Hackett 1986). The resultant metabolites can be re-absorbed and enter the entero-
hepatic cycle. Thus the half-life of elimination can be affected by the source and type 
of quercetin presented (aglycone/glucose/glycose) and plasma levels have detected 
quercetin up to 48 hours after its consumption (Hollman et al. 1996). This again 
suggests that repeated intakes of quercetin glycosides, which take longer to process, 
can cause a build-up of plasma concentration. 
 
1.6.3. Antioxidant properties 
A full discussion of the biological activity of polyphenols is beyond the scope of this 
thesis, therefore this section will focus on the antioxidant mechanisms of polyphenols. 
 
Historically, the biological effects of flavonoids have been controversial. With their 
discovery in the 1930/40s they were thought to have vitamin-like properties. Later, in 
the 1970s they were suspected mutagens and carcinogens, whereas the 1980s focused 
on their anti-mutagenic and anti-carcinogenic effects. More recent years have reported 
of their antioxidant capacities.  
 
Renewed interest has stemmed from epidemiological studies showing an inverse 
relationship between increased consumption of flavonoids and reduced risk of 
cardiovascular disease. Quercetin content measured in various foods (and other 
flavonoids) by Hertog et al (1992) is generally used as a reference database. 
Assessment of flavonoid intake from dietary food can then be linked with health 
during a follow up period. The Zutphen Elderly Study is a published epidemiological 
study which assessed flavonoid intake of 805 men aged 65 to 84 years and found a 
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significant inverse relationship between dietary flavonoid intake and mortality from 
coronary heart disease (CHD) and a slightly weaker inverse association with incidence 
of myocardial infarction. The findings remained significant after correcting for known 
major confounding factors (Hertog et al. 1993a). In southern France, a high intake of 
saturated fatty acids was not correlated with increased CHD risk and a high consumption 
of red wine, rich in flavonoids, was proposed to explain this ‘paradox’ (Ferrieres 2004). 
Vascular endothelium is important for maintaining cardiovascular health and several 
clinical trials have examined the effect of flavonoid-rich food and drinks on 
endothelium-dependent vasodilation. One trial involving 66 patients with coronary 
heart disease,  found that daily consumption of 4/5 cups (approximately 900 - 1250 
ml) of black tea for four weeks significantly improved endothelium-dependent 
vasodilation compared to caffeine or hot water alone (Duffy et al. 2001).  A smaller 
trial of 15 patients showed improvement of vasodilation and reduced LDL 
susceptibility to oxidation, after daily consumption of purple grape juice (3 cups ~ 640 
ml) for 2 weeks (Stein et al. 1999). 
 
Oxidation of low density lipoproteins (LDL) is a free radical process known as lipid 
peroxidation, which oxidises unsaturated fatty acids in LDL. This can initiate and 
develop atherosclerotic plaques, leading to cardiovascular diseases. Flavonoids exert 
their antioxidant activity here by interfering with this oxidation process, namely by 
rapidly donating hydrogen to radicals.  
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(i) R• + Flavonoid-OH → Flavonoid(O•) + RH 
(ii) R• + Flavonoid(O•) → R-Flavonoid 
 
R• denotes a free radical and O• denotes a reactive oxygen species 
 
In reaction (i) the flavonoid radical intermediates are a more stable product therefore a 
new chain reaction cannot be easily initiated. The flavonoid radical intermediates 
themselves can also terminate further propagation by reacting with other free radicals 
(reaction ii). 
 
Quercetin also reduced the cytotoxicity of oxidized LDL on lymphoid cell lines 
(Negre-Salvayre and Salvayre 1992). The exact mechanisms are not known but it is 
speculated that quercetin may block the generation of intracellular cytotoxic signals, 
possibly by inhibiting enzymes that are involved in signal transduction. An emerging 
view is that quercetin can affect protein kinases to modulate cell signalling. Signal 
transduction requires kinases to phosphorylate target proteins at specific sites to 
ultimately affect gene expressions. Recent in vitro work using primary cortical neuron 
has shown that quercetin and its metabolites can act on numerous kinases 
(phosphoinositide 3-kinase (PI3-kinase), Akt/protein kinase B (Akt/PKB), tyrosine 
kinases, protein kinase C (PKC)) (Spencer et al. 2003, Williams et al. 2004) which 
may have profound effects on cellular functioning. Therefore it is clear that a better 
understanding is needed of quercetin as a cell-signalling modulator in its evaluation as 
a cardio-protectant.  
 
  1. Introduction 
 
53 
The antioxidant efficiency of flavonoids depends on their chemical structure. 





double bond, a carbonyl group in carbon position four and poly-hydroxylation 
of the A and B aromatic rings (Rice-Evans et al. 1996, Cook and Samman 1996). 
Quercetin possesses all these characteristics making it one of the most potent natural 
antioxidants (Bravo 1998).  
 
An important antioxidant mechanism of quercetin is as an effective iron chelator. 
Quercetin is suggested to interfere with iron absorption by forming insoluble iron 
complexes in the gastrointestinal lumen thus reducing iron bioavailability (Ma et al. 
2010). This may have therapeutic implications in pathological conditions of iron 
overload. In cultures of iron-loaded rat hepatocytes, quercetin was efficient at 
sequestering iron from cells, revealing a good relationship between iron-chelation and 
cytoprotective effects (Morel et al. 1993). In the native state, iron can initiate free 
radical production by the Fenton and Haber-Weiss reactions but flavonoids like 
quercetin that possess both a C-4 carbonyl group and a C-3 or C-5 hydroxyl group, 
can chelate iron thus preventing iron-induced free radical formation (Afanas'ev et al. 
1989).  
 
Quercetin can protect against reactive oxygen species of different origins. Smoking is 
an environmental cue that generates free radicals in the body, damaging erythrocyte 
membranes as one of its many detrimental effects. Begum and Terao (2002) found 
that quercetin and its potential metabolites (quercetin-3-O-β-glucuronide and 
quercetin-3-O- β -glucoside) suppressed erythrocyte damage as well as the associated 
  1. Introduction 
 
54 
membrane lipid peroxidation (Begum and Terao 2002). This shows that it is not only 
quercetin aglycone but also its conjugate metabolites that are capable of scavenging 
free radicals. 
 
The abundance of flavonoids in the diet suggests they have been conserved to provide 
great nutritional benefits. Quercetin being the major constituent of flavonoid intake 
could be key in protecting against several chronic diseases. It has all the structural 
requirements to be a powerful antioxidant, and its cytoprotective effects have been 
noted in epidemiological and in vitro studies. However, further work is needed to 
better understand the effects of quercetin within the human body including rate and 
extent of its absorption, metabolism, and bioavailability.  
 
Quercetin is able to suppress propagation of free radical formation by interfering with 
the lipid peroxidation process and chelating iron which may otherwise cause free 
radical production by the Fenton reaction. These provide some mechanisms for the 
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1.7. Polyphenol and iron interaction 
1.7.1. Nuclear factor erythroid 2-related factor 2 (Nrf2) 
The nuclear factor erythroid 2-related factor (Nrf2) is a transcription factor that 
functions as a key inducer of antioxidant and detoxifying enzymes through its binding 
to antioxidant response elements (ARE). During conditions of oxidative stress, the 
Nrf2 signalling pathway is activated (Figure 1.14). In the cytoplasm, kelch-like ECH-
associated protein 1 (Keap1) interacts with Nrf2 as an inactive complex, promoting 
rapid Nrf2 ubiquitination and degradation (Itoh et al. 1999). Increased intracellular 
ROS weakens this Keap1-Nrf2 interaction and Nrf2 is stabilised, allowing it to 
dissociate from Keap-1 and translocate to the nucleus. Here it associates with its 
transcriptional partner, Maf proteins, forming a heterodimer that binds to antioxidant 
response elements of DNA, activating transcription of a whole host of cytoprotective 
genes (Itoh et al. 1997). 
 
Recently it has been suggested that quercetin may be able to activate this Nrf2 
pathway (Granado-Serrano et al. 2012). In the human hepatoma cell line (HepG2) it 
was shown that 10 µM quercetin was able to regulate Nrf2 by up-regulating the 
phosphorylation and translocation of Nrf2. This phosphorylation process has been 
described as critical for its nuclear translocation and transcriptional activity (Pi et al. 
2007). Therefore it seems as though the actions caused by quercetin on Nrf2 may be 
important for defending cells against ROS insult and maintaining a favourable redox 
balance. 
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Ferroportin is essential for the control of iron efflux therefore its possible regulation 
by Nrf2 is of major interest. Bioinformatics analysis revealed four putative 
MARE/ARE (Maf Recognition Element/Antioxidant Responsive Elements) motifs, 
upstream of the macrophage FPN transcription site, one of which is located within a 
highly conserved FPN promoter region (Marro et al. 2010). Using luciferase 
constructs, mutation of this MARE/ARE sequence (at position -7007/-7016) resulted 
in abolished haemoglobin-induced activation of luciferase activity suggesting it is 
essential for regulating FPN transcription in response to haemoglobin.  Further studies 
are required to see if non-haem iron is able to cause similar activation and whether 




















Figure 1.14 Activation and induction of Nrf2 signalling pathway 
Nrf2 is kept in an inactivate complex with Keap-1 in the cytoplasm. ROS stimulates 
dissociation of Nrf2 and translocation to nucleus.  Nrf2 binds with Maf protein, and binds to 
ARE sequences in the promoter region of genes encoding antioxidant and detoxifying 
enzymes. 
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1.7.2. Polyphenol and iron interaction in the diet 
Polyphenols exert a number of effects, and as previously mentioned, polyphenols can 
chelate iron, which is one way they affect non-haem iron bioavailability. Another 
mechanism more recently shown is that quercetin may act as a substrate for DcytB, 
the endogenous apical ferric-reductase (Vlachodimitropoulou et al. 2010). This may 
increase the reducing potential of DcytB, providing more Fe
2+
 for DMT1-mediated 
cellular uptake. Quercetin being lipophilic can easily cross lipid bilayers but it has 
been stipulated that when it binds to iron, it forms stable quercetin-iron complexes 
which are redox-inactive (Baccan et al. 2012). These complexes may be able to enter 
cells via glucose transporter proteins (GLUTs). Quercetin can utilise GLUT-1, -3 and 
-4 to enter cells and acts as an inhibitor of dehydroascorbate and glucose transport 
when using the same transporters (Strobel et al. 2005, Vlachodimitropoulou et al. 
2011). GLUT-1, which is the only endogenously expressed glucose transporter in 
MDCK cells (Madin Darby canine kidney cells), has been shown to be capable of 
transporting the chelated-complex in either direction across the cell membrane 
(Vlachodimitropoulou et al. 2011). The possibilities then are that these complexes are 
too large to be exported out by ferroportin leading to increased intracellular iron 
levels, or that these complexes may be exported out by GLUT-1 thus quercetin acts as 
a siderophore (a compound that bind iron for removal or delivery to cells). Another 
study found that glycosylated quercetin such as rutin are able to pass cell membranes 
but only free quercetin is able to access the cytosol to decrease intracellular labile iron 
pools (Baccan et al. 2012). 
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Quercetin interaction with iron has shown itself to be multi-faceted. Quercetin can 
directly scavenge free radicals; it is an iron chelator and can thereby inhibit iron-
induced free radical production; it is an electron donor to DcytB which in turn reduces 
iron to a more soluble form (Fe
2+
). Quercetin is membrane-permeable via GLUTs, so 
can easily enter the cell cytosol for iron chelation. Quercetin-iron complexes are 
stable, non-reactive and can possibly enter/exit cells by GLUT-1. Aglycone quercetin 
can decrease iron present in the cytosol by speeding up its passage across the cell 
membrane and loading on to the iron transport protein transferrin.  
 
Although there are several mechanisms in place to regulate iron, imbalances can still 
occur. Iron overload occurs in primary hereditary haemochromatosis, which is caused 
by mutations in genes important for iron regulation. Mutations include genes encoding 
for haemojuvelin, hepcidin, transferrin receptor-2 (Tfr2) and ferroportin. Lack of 
hepcidin (or low levels) means there is no negative signal to stop iron absorption even 
when the systemic level of iron is high. Mutations in ferroportin can impair iron 
export, giving rise to intracellular iron accumulation, or cause ferroportin resistance to 
hepcidin, which results in constant iron export, iron-loading the rest of the body. 
Secondary iron overload can be caused by repeated blood transfusions in 
haematological disorders like thalassaemia (Papanikolaou et al. 2005). Current 
treatment for secondary iron overload includes chelators such as desferrioxamine 
(DFO), deferiprone or deferasirox. DFO has to be administered intravenously or 
subcutaneously which has poor patient compliance. Deferiprone has been an oral 
alternative but severe gastrointestinal complaints are frequent with commonly 
reported side effects of nausea and vomiting (Eshghi 2007). This, alongside patient 
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neglect to take the drug three times a day for prolonged periods causes problems with 
prescribed deferiprone regimen. 
 
There are certain conditions where iron overload may occur in select areas without 
causing general hyperferraemia. In anaemia of chronic disease, plasma iron levels are 
very low but macrophages contain high amounts by withholding iron. Certain 
neurodegeneration disorders accumulate iron within the brain. Using general iron 
chelators for these disorders may be inappropriate; rather a better therapeutic approach 
would be to target its redistribution (Kakhlon et al. 2010). Ideally, to be able to do 
this, chelators should be able to penetrate iron-overloaded tissue, form stable and 
redox-inactive species (to decrease intracellular labile iron) and transfer it to 
circulating transferring (Baccan et al. 2012) . Quercetin meets all the requirements and 
its role as a ‘shuttle’ for iron may be of particular use for iron-redistribution therapy.  
 
Polyphenols constitute one of the most ubiquitous compounds in the plant kingdom 
thus forming an integral part of human diets. Quercetin, belonging to the flavonoid 
group, represents one of the most common and widely distributed plant polyphenols. 
It can bind iron by forming complexes through its carboxyl and hydroxyl groups, and 
consequently is capable of interfering with intestinal iron absorption. Polyphenol 
supplementation is becoming more frequent in food and health industries therefore the 
nutritional significance of quercetin and its potential health benefits requires more 
detailed studying. As deregulation of iron is implicated in the development of many 
diseases, polyphenols may have important applications in their treatment. To fully 
understand the actual significance of polyphenols, it is necessary to investigate their 
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mechanisms of action. It is important to define how dietary polyphenols interact with 
our intake of essential nutrients like iron as only then can we correctly recommend 
and optimise intake for different health and disease states. These mechanistic factors 
comprise the main body of research for this thesis.  
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1.8. Aims of study 
 
The aim of this study was to use biologically relevant in vitro models to elucidate the 
mechanisms underlying the effects of quercetin, the most abundant flavonoid, on iron 
metabolism.   
 
The Caco-2 cell line was utilised as a model of intestinal enterocytes to investigate the 
effects of quercetin on iron bioavailability and gene expression. To deduce the 
molecular mechanisms of quercetin on iron absorption, cells were transfected with 
ferroportin promoter constructs. Ferroportin 3’UTR and activation of miRNAs were 
also explored.  
 
HepG2 hepatocarcinoma cells were used to model hepatic iron storage. As the site of 
hepcidin production, effects of quercetin on hepcidin expression and intermediates in 
the hepcidin signaling cascade were investigated. Liver pathology is often changed in 
iron-overload diseases thus the effect of quercetin on iron-induced changes in cell 
proliferation and viability were also examined. 
 
Thp1 cell line represented macrophage iron-recycling system and was used to study 
changes in iron transporter gene expression induced by iron and quercetin and their 
effects on FPN promoter. 
 
  





The starting hypothesis was that quercetin would alter the expression of genes 
involved in iron metabolism via its action as an iron chelator, thereby reducing 
intracellular iron levels. 
 
An alternative hypothesis is that quercetin acts independently of changes in cellular 
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2.1. Cell Culture 
2.1.1. Cell culture material 
 
Table 2.1. Cell culture material and reagents 
Material Description Supplier Cat 
No. Media Dulbecco’s Modified Eagle Medium (DMEM) Invitrogen 41965-
062 




Serum Fetal Bovine Serum (FBS), Heat-inactivated Invitrogen 10108-
165 
Trypsin TrypLE(TM) Express  Invitrogen 12605-
010 
Supplement Penicillin 10,000 U/ml (100x) Invitrogen 15140-
122 
Supplement Streptomycin 10,000 µg/ml (100x) Invitrogen 15140-
122 
Supplement L-Glutamine 200 mM (100x) Invitrogen 25030-
024 
Supplement MEM Non Essential Amino Acids 10 mM (100x) Invitrogen 11140-
035 
Supplement Plasmocin, prophylaxis 2.5mg/ml InvivoGen Ant-
mpp 
Dye Trypan blue Sigma-Aldrich T8154 









Treatment Hemin Sigma-Aldrich H9039-
1G 




Treatment LY294002 (PI3K inhibitor) Calbiochem 440204 
Treatment HIF-2α inhibitor Calbiochem 400088 
Treatment HIF-2α inhibitor Calbiochem 400087 
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2.1.2. Cell culture 
All cells were maintained at 37ºC in an atmosphere of 95% air and 5% CO2 using 
Nunc tissue culture plastics. The media (DMEM) contained 10% (v/v) fetal bovine 
serum, 1% (v/v) non-essential amino acids, 2 mM L-glutamine (10% v/v), 100 U/ml 
penicillin (10% v/v), 100 μg/ml streptomycin (10% v/v), and 2.5 mg plasmocin (0.2% 
v/v). Media was refreshed every other day. All supplements were filtered through a 
0.2 µm pore size filter before adding to media. Medium was changed to serum-free 24 
hours before treatment to cause growth arrest and therefore keep all the cells in the 
same phase of the growth cycle. To subculture Caco-2 and HepG2, media was 
removed and briefly washed with PBS for 5 seconds. 0.2% (v/v) Trypsin was added to 
stimulate detachment for a period of 10 min, after which an equal volume of serum-
containing media was added to deactivate trypsin activity. Cells were collected in a 50 
ml falcon tube and centrifuged at 900-1000 rpm for 5 min. Supernatant was removed 
and cell pellet was resuspended in 10 ml of new culture medium and cell numbers 
were determined with a haemocytometer.  
 
A Trypan blue exclusion test was used to estimate cell number and viability. Viable 
cells have an intact cell membrane and appear clear under the microscope whereas 
dead cells have a damaged membrane, allowing the Trypan blue to leak in and stain 
the cell. 10 µl of cell suspension with Trypan blue in a 1:1 ratio at 0.2% (w/v) was 




 of cell 
suspension and counting only viable cells, the number of cells in the original sample 
was calculated as follows: Cells per ml = (Number of live cells counted) x 10
4
 X 
(dilution factor). The dilution factor was always 2.  




Thp1 remained in cell suspension. To renew media every 2 days, cells were collected 
in a 50 ml falcon tube, centrifuged, supernatant removed, fresh media added and then 
placed back in flask. The same occurred for sub-culturing, except cells underwent 
Trypan blue test and haemocytometer counting to determine quantity. This occurred 
every 3-4 days. 
 
Stocks of all cells were stored at a density of 1 x 10
7
 cells/ml of freezing medium 
(30% FBS supplemented media and 5% DMSO) in cryovials. These were initially 
stored at -80 °C in a "Mr. Frosty" 5100 Cryo 1°C Freezing Container (Nalgene) for 24 
hours and then transferred to liquid nitrogen for long term storage. 
 
2.1.3. Cell culture for experiments 
For RNA and protein isolation, Caco-2 cells were seeded for 21 days in normal 
culture medium to allow full differentiation (density stated in Table 2.1.2). Media was 
changed to serum-free on day 21 to arrest cell growth and treatment with normal 
media occurred on day 22. HepG2 cells were plated for two days followed byserum-
free media for one day and thereafter treatment with normal media. THP1 cells were 
seeded for 24 hours, 100 nM PMA in DMSO was added for a further 24 hours to 
promote differentiation of monocytes into macrophages. The PMA-containing media 
was removed and replaced with serum-free media for 24 hours before treatment. 
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Table 2.2 Cell plating density (cells/well) and time required for growth 
Cell type 6-well plate 12-well plate Growth 
period 
Caco2 4 X 104 2 x 104 21 days 
HepG2 5 X 105 2.5 X 105 2 days 
THP1 1 X 106 5 X 105 1 day (+1day 
PMA) 
 
Cells were seeded at different densities according to the plate size and cell type 
 
2.2. q-PCR (Real time PCR) 
2.2.1. RNA isolation 
TRI Reagent (Sigma) was used to isolate RNA from cells. 1 ml of TRI Reagent was 
added to each well of a 6-well plate (0.5 ml for 12-well plate). Cells were incubated at 
room temperature for 5 min to allow complete dissociation. The solution was 
transferred into a 1.5 ml Eppendorf and 200 μl/ml of chloroform was added (1:5) and 
thoroughly mixed by hand for 15 seconds to precipitate proteins. After 10 min room 
temperature incubation, samples were centrifuged at 12000 g for 15 min at 4°C 
causing the solution to separate into 3 layers. The colourless upper aqueous phase 
containing the RNA was transferred to a fresh Eppendorf. RNA was precipitated by 
adding 500 µl of ice-cold isopropanol (Sigma, Cat No. 19516) to the Eppendorf at 
room temperature for 10 - 15 min and then centrifuging at 12000 g for 10 min at 4°C. 
Isopropanol was removed and the pellet washed with 1 ml of 75% ethanol (Sigma-
Aldrich, Cat No. E7023) by vortexing followed by centrifugation at 7500 g for 5 min 
at 4ºC. Ethanol was discarded and the final RNA pellet air-dried. To dissolve RNA, 20 
- 30µl RNAse-free water was added and kept at 60ºC for 5 - 10 min. After this, RNA 
samples were kept on ice at all times. 
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Concentration of extracted RNA was measured using a NanoDrop® 
spectrophotometer ND-1000 (NanoDrop, USA). Quality was assessed by using the 
A260/280 and A230/260 ratio. RNA with a ratio higher than 1.9 for A260/280 
confirms there is no protein contamination and a ratio higher than 1.5 for A230/260 
indicates no solvent contamination.  
2.2.2. Reverse transcription 
Complementary DNA (cDNA) was synthesized from 1 μg of total RNA by using a 
High Capacity cDNA Reverse Transcription Kit with RNase Inhibitor (Applied 
Biosystems, Cat No. 4374966). Using the Nanodrop RNA measurements, the volume 
needed for 1 µg RNA was calculated and transferred to a PCR tube and made up to 10 
µl by adding RNAse-free water. Following the manufacturer’s protocol, a master mix 
was made (Table 2.3) and 10 µl of this was added to each tube PCR tube. Tubes were 
centrifuged and placed in a thermal cycler in the following optimised conditions: 
Primer incubation; 25ºC for 10 min, Reverse transcription; 37ºC for 120 min, and 
enzyme inactivation; 85ºC for 5 min. Samples were kept at 4ºC for immediate use or 
at -20 ºC to be used later. 
 
Table 2.3 Reverse transcription 2x master mix components 
Component Volume 
(µl)/reaction 
10×RT Buffer 2.0 
25× dNTP Mix (100mM) 0.8 




RNase Inhibitor 1.0 
Nuclease-free H2O 3.2 
Total per reaction 10.0 
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2.2.3. Real-time PCR  
The fluorescence readings were recorded at the annealing step (Table 2.5). Data was 
analysed using the ABI Prism software. The gene expression data were normalized to 
individual 18S RNA expression.  
Real time PCR was performed on 1µl of cDNA reaction mixture using the ABI Prism 
7000 sequence detection system thermo cycler (Applied Biosystems) coupled with 
SYBR green technology (Qiagen GmBH, Germany). SYBR green is a fluorescent dye 
that binds to the minor groove of DNA and fluoresces only when bound to double 
stranded DNA. The intensity of the signal is proportional to the amount of amplified 
DNA detectable during each cycle and the cycle threshold is defined as the first cycle 
in which there is a significant increase of the signal. Passive-reference dye called 
ROX normalises for any non-PCR fluorescence, for example variations in volumes 
between wells. By plotting Ct values against a standard curve, it is possible to 
calculate the relative quantity of a specific gene. 
 
Samples were prepared in 96-well PCR semi-skirted plates (Starlab UK) with a final 
volume of 25 µl. Master mixes were prepared for each primer pair as described in 
Table 2.2.2. cDNA was directly used for each gene but was diluted for housekeeping 
gene 18S ribosomal RNA (1:100 dilution) due to its extremely high expression. A 
standard curve was generated for each gene using a set of five standard dilutions (1, 
0.1, 0.01, 0.001, 0.0001) which were prepared from a pool of templates. This was run 
on each plate alongside the unknown samples to quantify efficiency of amplification 
as well as two non-template controls which did not contain any sequence to check for 
contamination.  
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Table 2.4 Components of qPCR reaction plate 
Component Volume/reaction Final concentration 
2x QuantiTect SYBR Green PCR Master Mix 12.5 µl 1x 
Forward Primer 1.25 µl 0.5 µM 
Reverse Primer 1.25 µl 0.5 µM 
RNase-free water  10 µl ---- 
Template (cDNA or Standard) 1 µl ~1000 ng/reaction 
Total volume 25 µl ---- 
 
 
qPCR plates were centrifuged and placed in the ABI Prism 7000 real-time cycler with 
the following programme:  
 
Table 2.5 q-PCR cycling parameters 
Cycles Temp (°C)  Time Comment 
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18S AACTTTCGATGGTAGTCGCCG CCTTGGATGTGGTAGCCGTTT 
BMP6 CCGTGTAGTATGGGCCTCAGA TCACAACCCACAGATTGCTAGT 
DcytB GCATCGCCATCATCGTCTACA ACGGCCACCACAGAGATAATT 
DMT1+IRE AGTGGTTTATGTCCGGGACC TTTAACGTAGCCACGGGTGG 
Ferroportin (FPN) CCACAATACGAAGGATTGACCA GGA CGT ACT CCA CGC ACA TG 
FPN1A AAAGAAGACCCCGTGACAGC TCCCCTTGTTTGTTCTGATG 
FPN1B GCCGGTTGGAGTTTCAATGT TCCCCTTGTTTGTTCTGATG 
Hephaestin CACACCATGCACTTTCATGC GCATGCACATGGTCAGTCAC 
Hepcidin CTGCAACCCCAGGACAGAG GGAATAAATAAGGAAGGGAGGGG 
SMAD4 GATACGTGGACCCTTCTGGA ACCTTTGCCTATGTGCAACC 
 
2.3. Western blotting 
2.3.1. Protein isolation 
After treatment, media was removed from 6-well plates and washed briefly with PBS. 
100 µl of protein lysis buffer (Table 2.7) was added per well and placed on a rocker 
for 10 min. A cell scraper was used to detach the cells, and collected into a 
corresponding Eppendorf where it was homogenised through a 25 gauge needle to 
promote cell lysis. After centrifugation (13,000 rpm for 10 min at 4°C) to remove cell 
debris, the supernatant was transferred to a fresh Eppendorf and kept on ice for 
quantification. 
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Table 2.7. Protein lysis buffer 
Material Description  Conc. Supplier Cat No. 
PBS Phosphate buffered saline N/A Oxoid BR0014G 
PI Protease Inhibitor Cocktail  1:100 Sigma-Aldrich P8340 
SDS Sodium dodecyl sulphate 1:1000 Sigma-Aldrich 71727 
 
 
2.3.2. Nuclear and cytoplasm protein extraction  
Nuclear proteins are more concentrated in nuclear extracts than in whole cell lysates. 
To isolate nuclear and cytoplasmic proteins, NE-PER Nuclear and cytoplasmic 
Extraction Reagent (thermo Scientific Cat No 78833) kit was used and the 
manufacturer’s protocol followed. 
 
Caco-2 cells were harvested with trypsin-EDTA and centrifuged at 500 x g at 4°C for 
5 min. All samples and extracts from this point forward were kept on ice and all 
centrifugation performed at 4°C. The cell pellet was suspended in PBS and 
centrifuged at 500 x g for 2 - 3 min. The supernatant was carefully discarded to leave 
the pellet as dry as possible. Protease inhibitor was added to CER I and NER just 
before use. 100 µl ice cold CER I was added to the pellet and vortexed to fully 
suspend the pellet and kept on ice for 10 min. Ice cold 5.5 µl CER II was added to the 
sample, briefly vortexed for 5 seconds before incubating on ice for 1 minute. It was 
briefly vortexed again, and centrifuged at the highest speed for 5 min. The supernatant 
(cytoplasmic extract) was immediately transferred to a fresh Eppendorf and kept at 
4°C until use.  
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The remaining cell pellet was suspended in 50 ul ice-cold NER and vortexed. The 
sample was kept on ice and vortexed for 15 seconds, every 10 min, for 40 min. After 
this, the sample was centrifuged at the highest setting for 10 min and the supernatant 
(nuclear extract) immediately transferred to a fresh Eppendorf. Different volumes of 
reagents could be used depending on cell volume as long as a volume ratio of CER 
I:CER II:NER at 200:11:100 µl was maintained. Extracts were stored at -80°C until 
use.  
 
2.3.3. Protein quantification 
Protein concentration was determined using the BioRad Protein Assay Kit (Bio-Rad, 
Germany, Cat No 500-0006), based on the Coomassie blue binding method which 
causes a shift in absorbance of the Coomassie reagent from red to blue when it binds 
to protein (Bradford, 1976) at OD595. A 1 in 5 dilution of the Bio-Rad dye was made 
(provided as a 5 x concentrated solution) with ddH2O to be used for the assay. 10 μl of 
protein sample were dissolved in 90 μl of 200 mM Sodium Hydroxide (NaOH). Serial 
dilutions of bovine serum albumin (BSA) were used as standard concentrations (stock 
was 1 mg/ml; dilution range: 0, 5, 10, 20, 50, and 75 µg) and made up with NaOH to a 
final volume of 100 µl.  4 ml of diluted Bio-Rad solution was added to each tube. The 
absorbance was read at 595 nm and plotted against the standard concentrations. This 
generated a standard curve to quantify protein concentration of the samples.  
 
2.3.4. SDS-PAGE 
Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) is formed 
by the polymerization of acrylamide and bis-acrylamide, to separate proteins 
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according to their size. Normally a 10% gel was used unless the protein had a 
molecular weight greater than 120 kDa in which case an 8% gel was used. Table 2.8 
shows the materials used to prepare the gel. 
 
Table 2.8 Materials and volumes required to make 1 SDS-PAGE resolving gel 
Material Description Supplier 
Cat 
No. 




--- --- --- 4.095 ml 3.525 ml 
Acrylamide 
40% 





1.575 ml 1.875 ml 
Tris 1.5M 
pH8.8 
Tris Base (1.5 M, pH= 8.8) VWR 
10315
6X 
2.047 ml 1.95 ml 
SDS 10% 




71727 78.75 µl 75 µl 









Sigma T9281 10.5 µl 10 µl 
 
 
A gel casting cassette was assembled using 2 glass plates with a silicone rubber seal 
in-between and clipped together. The resolving mixture (Table 2.8) was poured in 
between the glass plates and a 14-well comb was inserted at the top. The solution was 
left to set for 15 - 30 min at room temperature after which the comb and seal were 
removed and any gel residues washed away with water. It was then placed in an 
electrophoresis gel tank. 1 x running buffer (Table 2.10) was poured into the tank till 
the wells were completely immersed. 
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A minimum of 20 μg of protein was mixed with an equal volume of 2 x Laemmli 
loading buffer (Table 2.9) and loaded on to the gel along with 7 μl of rainbow 
molecular marker (GE Healthcare, USA, Cat No. RPN800E) in the first well of each 
gel. The gels were run at 30mA (per gel), 220 V for 90 min or until the bromophenol 
blue dye in the Laemmli loading buffer reached the bottom of the gel. 
 
Table 2.9 2x Laemmli loading buffer 
Material  Final Conc Supplier  Cat No. 
SDS (w/v) 2% Sigma-Aldrich 71727 
Tris (pH=6.8) 62.5 mM VWR 103156X 
Glycerol (v/v) 25% Sigma-Aldrich G5516 
Bromophenol blue (w/v) 0.01% VWR 20017 
β-mercaptoethanol (v/v) 14.4 mM (10%) Sigma-Aldrich M7522 
 
Table 2.10 Running buffer 
Material Final Conc Prep. Supplier Cat No 
Tris Base 25 mM 3 g/l VWR 103156X 
Glycine  250 mM 19 g/l Sigma-Aldrich G8898 
SDS  0.02% (w/v) 0.2 g/l Sigma-Aldrich 71727 
 
Table 2.11 Transfer buffer 
Material Final Conc Supplier Cat No 
Tris Base 25 mM VWR 103156X 
Glycine  190 mM Sigma-Aldrich G8898 
SDS  0.037% (w/v) Sigma-Aldrich 71727 
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Table 2.12 Phosphate buffered saline-Tween20 (PBST) 
Material Final Conc Supplier Cat No 
PBS (1x) N/A Oxoid BR0014G 
Tween 20 (v/v) 0.1% Sigma-Aldrich P5927 
 
 
Proteins were transferred from the gel to nitrocellulose membrane (GE Health care, 
USA) using a Trans-Blot semi dry electrophoresis transfer cell. To do this, gels were 
allowed to equilibrate in transfer buffer (Table 2.11) for 15 min to remove any salt or 
detergent. Nitrocellulose membrane was cut to the size of the gel and 2 pieces of 
slightly larger filter paper were soaked in transfer buffer for 2 min. The pre-soaked 
filter paper was placed on the machine and the nitrocellulose on top of the filter paper. 
The gel was placed gently on top of the nitrocellulose membrane and another filter 
placed on top of the gel. Any air bubbles between the layers were rolled out using a 
pipette. The cathode lid was placed on top and the machine set to transfer at 70 
mA/gel for 70 min. 
 
2.3.5. Protein detection  
Nitrocellulose membrane was incubated in 5% blocking buffer (2.5 g in 50 ml PBST) 
for a minimum of 1 hour at room temperature on a shaker. In a 50 ml falcon tube, 
primary antibody was diluted in 1% milk and the nitrocellulose membrane placed 
inside on a roller for overnight incubation at 40 rpm at 4 °C. 
 
The membrane was washed three times for 5 min with PBST and then placed in a 50 
ml tube with 1% milk containing the appropriate HRP-conjugated secondary antibody 
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at 40 rpm for one hour at room temperature. The membrane was finally washed 3 
times with PBS and protein bands developed using the ECL plus western blotting 
reagent kit (GE Healthcare, USA, Cat No. RPN2132). Following the manufacturer’s 
protocol, developing (A) and enhancer solutions (B) were mixed in a 40:1 ratio and 
added to the membrane for 5 min. Excess solution was drained and the nitrocellulose 
membrane was placed between 2 transparent plastic sheets inside a developing film 
cassette. In a dark-room, X-ray film (Hyperfilms ECL, GE Healthcare, USA, Cat No. 
28906837) was exposed to the membrane to detect chemiluminescence. The 
incubation period varied for different proteins. For visualisation of the protein bands, 
the film was placed in developing solution (Kodak processing chemical, GBX 
developer, Sigma-Aldrich, USA, Cat No. P7042) till bands appeared, then washed 
with distilled water and fixed in fixing solution (Kodak processing chemical, GBX 
fixer, Sigma-Aldrich, USA, Cat No. P7167). 
 
The relative movement of protein bands were compared against the molecular weight 
marker to ensure the correct protein was being analysed. Developed films were 
scanned and the intensity of bands was numerically quantified using Image J software. 
Data was normalised to a housekeeping protein. 
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Table 2.13 Antibodies used in western blotting system 
 
Antibody Type Raised in 
MW 
(kDa) 
Dilution Supplier Cat No. 
β-Actin Primary Rabbit 42 1: 1000 Sigma-Aldrich A2066 




DMT1±IRE Primary Rabbit 65 1:500 Alpha-Diagnostics 
NRAMP24-
A 
Hephaestin (Hp) Primary Rabbit 155 1:1000 Alpha-Diagnostics HEPH11-A 
Ferroportin Primary Rabbit 110 1:1000 Alpha-Diagnostics MTP11-A 











Goat anti rabbit Secondary ---- ---- 1:1000 Dako Ltd P044801 
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2.4. Ferritin assay 
 
Following treatment, protein was isolated and quantified from Caco-2 cells as 
described in section 2.3.1. To measure changes in ferritin levels caused by these 
treatments, a ferritin assay was performed using the Ferritin Linked Enzyme 
Immunoabsorbent Assay (ELISA) Spectro-ferritin kit (Ramco Laboratories Inc, ATI 
Atlas Ltd UK, Cat No. S-22). The manufacturer’s protocol was followed. Briefly, 
serial dilutions of human spleen ferritin were provided in the kit to create to a standard 
curve (6, 20, 60, 200, 600, and 2000 ng/ml). 10 μl of sample lysate was added to 
separate microwells provided in the kit; these were coated with anti-ferritin antibody. 
200 μl of conjugated anti-human ferritin was added to all wells and the plate was 
incubated at 200 rpm on a shaker for 90 min at room temperature. The wells were 
washed 3 times with distilled water and excess liquid was drained on tissue paper. 200 
μl of substrate solution was added to each well and the plate incubated for 30 min at 
room temperature at 200 rpm. The colour was developed by adding 100 μl of 0.24% 
potassium ferricyanide and mixing thoroughly. A well containing 200 µl substrate 
solution and 100 µl potassium ferricyanide was used as a blank. The plate was read 
within 1 hour using a HT-1 plate reader (Synergy, UK) at a wavelength of 500 nm and 
corrected to 600 nm. The results were calculated using the standard curve (absorbance 
of standards plotted against their ferritin concentrations) and normalised to protein 
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2.5. 55Fe uptake 
 
Caco-2 cells were grown on Transwell inserts with 3.0 µm pore size (Costar, Fisher 
Scientific Ltd, Cat No TKT-526-020J) in 6-well plates. Following treatment with 
quercetin (0, 10 µM, and 100 µM) for 24 hours, cells were washed with HEPES-
buffered salt solution (HBSS) pH 7.5, (containing NaCl 140 mM; KCl 5 mM; 
Na2HPO4 1 mM; CaCl2 1 mM; MgCl2 0.5 mM; HEPES 10 mM; D-glucose 5mM and 
bovine serum albumin (BSA) 0.2% w/v). To achieve a transepithelial gradient, 1.5 ml 
MES buffer (same composition as HBSS but HEPES is substituted for MES (2-(N-
morpholino) ethanesulfonic acid) and no BSA) pH 6.5 was added to the apical 
chamber and 2.5 ml HBSS (pH 7.5) to the basolateral chamber and cells were pre-
incubated at 37ºC for 20 min.  
 
Iron uptake was initiated by adding to the apical media, a mixture of ferrous 
sulphate:ascorbate (10:100 μM) and 37kBq/ml radioactive 55FeCl3 to provide 
approximately 500,000 DPM/well (disintegration per minute) (FeSO4 - Sigma UK, 
Cat No F8048-500G; ascorbic acid - Sigma UK, Cat No A4034-500G; Iron-55 
Radionuclide, 1mCi (37MBq), PerkinElmer, Cat No. NEZ043001MC). 
 
To measure uptake, cells were incubated at 37ºC for 20 min and to measure transport, 
the incubation period was 120 min. Incubation was terminated by washing cell 
monolayers three times with ice-cold HBSS, cutting the Transwell membrane and 
placing membrane in to a corresponding well on a 6-well plate that contained 200 mM 
NaOH where they were kept overnight at 4ºC to allow cell lysis. Basolateral media 
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was also collected in corresponding Eppendorfs to determine iron efflux. The next 
day, membranes were thoroughly scraped and cell lysates passed through a 1 ml 
syringe to further lyse cells. For iron uptake (retention) 150 µl cell lysate was added to 
vials containing 5 ml of scintillant and for iron efflux 250 µl of basolateral media was 
added to vials of 5 ml scintillant. Iron transfer was calculated as the sum of the iron 
retention plus basal efflux. 15 µl of radioactive iron mixture (
55
FeCl3, FeSO4-
ascorbate) was used to determine starting activity. A LS100C Liqiud Scintillation 
Counter (Beckman-Coulter, UK) was used on the tritium channel in 5 ml of scintillant 
for 10 min per vial. Cell lysates were also used to measure protein concentration using 
the Bio-Rad method previously described and uptake and transport measurements 
were corrected to their protein levels. 
 
2.6. MTS cell viability assay 
 
Caco-2 cells were grown on 24-well plates and after 24 hour treatment, cell viability 
was assessed using an MTS assay. The CellTiter96® AQueous One Solution Cell 
Proliferation Assay (Promega UK Ltd, Cat No G3580) uses the tetrazolium compound 
[3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium, inner salt; MTS] to provide a colourimetric method for determining cell 
viability. Tetrazolium salts, such as MTS, are pale yellow salts that can be reduced to 
form blue coloured formazan products by the cytochrome system in only live cells, 
thus the intensity of the colour produced is directly proportional to cell viability.  
After treatment, 100μl of growth media was removed from each well and placed in a 
well on a clear 96-well plate. 15 μl of thawed MTS solution was then added to each 
well and the plate incubated in the darkat 37°C for 3 hours. The absorbance was read 
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at a wavelength of 485nm using a fluorescence plate reader (FLUOstar OPTIMA, 
BMG Labtech). 
 
2.7. BrdU cell proliferation assay 
 
The BrdU proliferation assay (Calbiochem, Cat No HTS01) is an immunoassay that 
incorporates bromodeoxyuridine, a thymidine analogue, into newly synthesised DNA 
strands. This allows us to assess the amount of cells that are actively synthesising 
DNA and therefore proliferating.  
 
100 µl of HepG2 cells were seeded at 10
4
 – 106 /well in 96-well plate and left for 24 
hours for cell attachment. Stock BrdU label provided in the kit was diluted 1:2000 into 
fresh serum-free media to produce a working stock, 20 μl of which was pipetted into 
each well, alongside the treatment. Following 24 hour co-incubation, well contents 
were removed and the plate blotted on tissue paper. 200 μl of Fixative/Denaturing 
Solution was added to each well and left for 30 min at room temperature. Well 
contents were removed again. 100X Anti-BrdU Antibody was diluted 1:100 in 
Antibody Dilution Buffer, and 100 μl of this solution added to wells. The plate was 
incubated at room temperature for 1 hour. A working solution of 1X Wash Buffer was 
prepared by mixing 25 ml of 20X concentrated solution with 475 ml deionised water. 
After 1 hour incubation, wells were washed with the wash buffer three times and the 
plate blotted on paper towels. Reconstituted Peroxidase-linked Goat Anti-Mouse IgG 
was diluted 1:1000 in Conjugate Dilutent and passed through a 0.2 μm filter. 100 μl of 
this solution was added to wells and the plate incubated at room temperature for 30 
min. Wells were washed three times with 1X Wash Buffer and the whole plate 
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flooded with deionised water. The plate was inverted over a sink to remove contents 
and then blotted on paper towels. A fluorogenic substrate working stock solution (9 
parts fluorogenic substrate to 1 part fluorogenic peroxide solution) was prepared and 
100 μl of the solution added to wells. The plate was incubated at room temperature for 
30 min. 100 μl of Stop Solution was then pipetted into wells in the same order as the 
Fluorogenic Substrate working stock solution. The plate was measured using a 
fluorescence plate reader (BMG FLUOstar Fluorometer, OPTIMA, Labtech) 
measuring excitation at 355 nm and emission at 460 nm. Wells were read within 30 
min of adding the Stop Solution for accurate readings.  
 
2.8. Ferroportin promoter 
 
Three plasmids were used in this study to assess the effect of quercetin and other 
treatments on ferroportin promoter: pGL4 empty plasmid as a control, pGL4-
FPN1Bpm (FPN1B) and pGL4-FPN1Apm (FPN1A). FPN1B lacked the iron response 
element (IRE) whereas FPN1A contained the IRE. These were kindly gifted by Dr 
De-Liang Zhang (Molecular Medicine Program, National Institute of Child Health and 
Human Development, Bethesda, MD 20892, USA). 
 
2.8.1. Vectors 
The basic pGL4.10 vector (Promega, Cat No. E6651) does not contain any enhancer 
or promoter elements (Figure 2.1). The vector contains a multiple cloning region 
immediately upstream of the firefly luciferase reporter gene (luc2), into which the 
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FPN promoter was cloned in via XholI/HindIII sites, to drive expression of the 
reporter gene. 
 
The MISSION 3'UTR Lentiviral Plasmid Vector pLSG_UTR_RenSP expresses an 













Figure 2.1 pGL4.10 luciferase reporter vector 
The pGL4.10 vector was used to clone in FPN1A/FPN1B promoter in to the multiple cloning 
region. The promoter affects the expression of downstream firefly luciferase activity, 





















Figure 2.2 Lentiviral Plasmid Vector pLSG_UTR_RenSP 
 
2.8.2. Plasmid transformation 
The plasmids arrived on filter paper in an air-sealed plastic wallet. To extract the 
DNA, plasmids were cut from the filter paper and immersed in a corresponding 
Eppendorf of 200 μl nuclease-free water for 1 hour at room temperature. The 
concentration was measured on a Nanodrop spectrophotometer and the appropriate 
volume for 10 pg – 100 ng of DNA (typically 1 – 5 μl) was used to transform the 
plasmid into Escherichia coli (E. coli) competent cells using One Shot TOP10 
Chemically Competent E. coli kit (Invitrogen C4040-03).   
 
E.coli cells were thawed on ice from –80 °C for 30 min. The plasmid was added and 
mixed by gently flicking the tube several times and placed back on ice for 30 min. The 
mixture was then heat shocked at 42 °C for 30 seconds without shaking and placed 
immediately back on ice for 2 min. 250 μl room temperature SOC media (provided in 
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the kit) was added to each transformation and the cells were placed horizontally on a 
shaker at 225 rpm for 60 min at 37 °C. 25 μl of the reaction was spread onto pre-
warmed Luria-Bertani (LB) agar plates containing 50 μg/ml carbenicillin and 
incubated at 37 °C overnight. This gave rise to single colonies that had successfully 
incorporated the plasmid and were able to survive by having selective antibiotic 
resistance. 
 
A single colony was chosen, picked off the agar plate using a pipette tip and placed in 
200 ml of autoclaved LB broth (4 g LB broth powder (Sigma, Cat No L3022-250G ) 
in 200 ml water) with 50 μg/ml carbenicillin added at the end. The mixture was placed 
on a shaker at 200 rpm, 37 °C overnight. Cells were harvested the next day by 
centrifugation at 4 °C at 6000 x g for 15 min. To isolate the plasmid DNA, a QIAGEN 
Plasmid Midi Kit (QIAGEN, Cat No 12143) was used and manufacturer’s protocol 
followed. Briefly, after centrifugation, the bacterial pellet was resuspended in 6 ml of 
cell lysis buffer P1 and then mixed with 6 ml of buffer P2. After vigorous mixing by 
inverting, it was left to stand for 5 min at room temperature. 6 ml of pre-chilled buffer 
P3 was added, thoroughly mixed and lysate transferred to a QIAfilter cartridge 
(provided in kit) where it was left to stand for 10 min. After which the lysate was 
filtered in to a pre-equilibrated HiSpeed midi tip. The flow-through was discarded and 
the tip washed with 20 ml buffer QC by gravity flow. DNA was eluted with 5 ml of 
buffer QC and the eluate collected in a 15 ml falcon tube. DNA was precipitated by 
adding 3.5 ml of room-temperature isopropanol to the tube, mixed and incubated at 
room temperature for 5 min.  The eluate/isopropanol mixture was filtered through a 
QIAprecipitator and DNA washed with 2 ml of 70% ethanol. 1 ml of buffer TE was 
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added to a 5 ml syringe with the QIA precipitator attached and the DNA eluted in to a 
1.5 ml collection tube. 
 
The DNA obtained was quantified using the NanoDrop spectrophotometer and sent 
off for sequencing to DBS Genomics Durham University. The sequence received was 
viewed using FinchTV software and underwent nucleotide BLAST on online NCBI 
database (blast.ncbi.nlm.nih.gov/) to confirm the presence of FPN promoter sequence. 
 
2.8.3. Transfection 
Caco-2 cells were seeded onto 24 well plates until reaching 60 - 80% confluence 
(50,000 cells/well). After 24 hours, cells were transfected with empty pGL4 plasmid, 
FPN1A or FPN1B using FuGENE HD Transfection Reagent (Promega UK, Cat No 
E2311). A master mix was prepared for each plasmid (Table 2.8.1) and incubated at 
room temperature for 15 min before adding 25 μl to each well in a drop-wise manner. 
 
Table 2.14 Fugene transfection master mix 
Solution  Quantity  
Serum-free DMEM Up to 25 μl  
Fugene  0.75 μl  
Renilla  0.01 µg  
Plasmid  0.2 µg 
 
Fugene was added to serum-free DMEM and incubated at room temperature for 5 min after 
which plasmid DNA was added (DNA:Fugene = 1 μg:3 μl). After 15 min incubation at room 
temperature, 25 μl was added to each well. 
Following transfection, cells were treated 24 hours later. 
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2.8.4. Dual luciferase reporter assay 
The Dual-Luciferase Reporter Assay System (Promega UK, Cat No E1910) was used.  
 
After treatment, media was removed and cells were washed twice with PBS. After 
adding 100 μl/well of passive lysis buffer, samples were incubated on a shaker for 15 
min to ensure they were thoroughly lysed. 10 μl of cell lysate was added to 50 μl of 
LARII reagent (mixture of luciferase buffer and substrate as provided in the kit). The 
firefly luciferase signal was read with a GloMax 20/20 Luminometer (Promega, USA). 
After initial reading, Stop and Glo buffer, which consists of a firefly signal quencher 
and Renilla substrate, was added to the 1.5 ml Eppendorf and a second reading was 
taken for Renilla luciferase activity. Firefly luciferase activity was normalized against 
Renilla luciferase activity and the ratio calculated. 
 
2.9. miRNA array 
2.9.1. Sample preparation 
Fully differentiated Caco-2 cells were either untreated (control) or treated with 10 µM 
quercetin for 24 hours. RNA was isolated using TRI Reagent as previously described. 
Samples for each treatment group were pooled together into 2 separate Eppendorf 
tubes and RNA concentration was measured on a NanoDrop spectrophotometer. Each 
pooled sample was diluted with nuclease free water to give a total RNA concentration 
of 500-1000 ng and made up to 8 µl.  
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2.9.2. Poly-A tailing and FlashTag Biotin HSR ligation 
Keeping RNA on ice at all times, 2 µl RNA spike control oligonucleotides were added 
to each Eppendorf containing the pooled samples. The ATP mix was diluted in 1mM 
Tris 1:500 as directed by manufacturer’s protocol before being added to the samples 
as shown in Table 2.15 to give a final volume of 15 µl per Eppendorf. 
 
Table 2.15 Components needed for poly-A tailing 
Component Volume (µl) for 1 sample 
10X Reaction Buffer 1.5 
25mM MnCl2 1.5 
Diluted ATP mix 1.0 
PAP enzyme 1.0 
 
 
Each sample was gently mixed by hand, microfuged and then placed on a 37ºC heat 
block for 15 min. After incubation, the samples were microfuged briefly and placed 
on ice. 4 µl 5X FlashTag Biotin HSR Ligation mix was added, followed by 2 µl of T4 
DNA ligase to each of the samples. After gentle mixing and microfuge, the samples 
were incubated at room temperature for 30 min. The reaction was stopped by adding 
2.5 µl HSR stop solution, giving a final volume of 23.5 µl. 21.5 µl of this was used for 
the next stage. The mixture may be stored for 6 hours on ice or up to 2 weeks at -20ºC 
prior to hybridization on an Affymetrix GeneChip. 
  





Table 2.16 Hybridization cocktail 
Component Volume (µl) for 1 sample 
2X Hybridization mix 50 
27.5% Formamide 15 
DMSO 10 
20X Eukaryotic Hybridization controls 5 
Control oligonucleotide B2, 3nM 1.7 
 
 
All components listed in Table 2.8.3 were bought to room temperature (20X 
Eukaryotic Hybridization Controls was heated for 5 min at 65ºC) and added in the 
order listed to 21.5 µl of the biotin-labelled samples from section 2.9.2. The total 
volume was 103.2 µl for each sample. The mixture was incubated at 99ºC for 5 min 
and then at 45ºC for 5 min. 100 µl of each sample was aspirated and injected into a 
labelled, corresponding array. Care was taken to prevent evaporation or leaks. The 
arrays were placed on to trays and placed into pre-heated hybridization oven where 
they were incubated at 48ºC for 16 hours at 60 rpm.  
 
2.9.4. Washing and staining 
The arrays were removed from the oven after their incubation period and 
hybridization cocktail removed from each array. These may be stored at -80ºC for 
future use. Each array was then completely filled with Array Holding Buffer and left 
to equilibrate to room temperature.    
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600 µl stain cocktail 1; 600 µl stain cocktail 2 and 800 µl array holding buffer were 
loaded on to sample holders on the fluidics station as directed by manufacturer’s 
protocol. The programme was set to wash and stain with Fluidics station 450 using 
fluidics script FS450_0003. The arrays were checked for air bubbles and dust on the 
array glass surface before scanning.  
 
2.9.5. Analysis 
miRNA QC Tool Software was used for data summarisation, normalisation and 
inspecting quality control. After miRNA QC Tool analysis was run, data was exported 
to Microsoft Excel software for further analysis of fold changes of individual 
miRNAs. Selected miRNA showing significant changes were validated by q-PCR.  
 
2.10. miRNA validation 
miRNAs were validated using miRCURY LNA™ Universal RT microRNA PCR kit 
(Cat No 203301). RNA samples from quercetin-treated Caco-2 cells was diluted to 5 
ng/µl for reverse transcription.  Following the manufacturer’s protocol, a working 
solution was made (Table 2.10.1) and dispensed into nuclease free PCR Eppendorf 
tubes. After brief centrifugation, tubes were placed in a thermal cycler in the 
following conditions: incubation; 42ºC for 60 min, heat inactivate reverse 
transcriptase; 95ºC for 5 min and immediately cool to 4ºC for use or short-term 
storage. 
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2.10.1. Real-time PCR  
cDNA template was diluted 1:80 in nuclease free-water (e.g. add 395µl water to each 
5 µl of reaction). Primer:master mix working solution was prepared as in Table 2.10.2 
and added to well of PCR  plate. Plate was sealed and centrifuged (1500xg for 1 
minute). Real-time PCR amplification performed according to Table 2.10.3. 
 
Table 2.17 Reverse transcription setup per reaction 
Reagent Volume 
(µl)/reaction 
5 × Reaction Buffer 2.0 
Nuclease-free H2O 4.5 
Enzyme mix 1.0 
Synthetic RNA spike in (optional; 
replace with H2O if omitted) 
0.5 
Template total RNA (5 ng/µl) 2.0 
Total volume 10.0 
 
 
Table 2.18 Components of qPCR reaction plate 
Component Volume/reaction Final concentration 
2x QuantiTect SYBR Green PCR Master Mix 12.5 µl 1x 
Forward Primer 1.25 µl 0.5 µM 
Reverse Primer 1.25 µl 0.5 µM 
RNase-free water  10 µl ---- 
Template (cDNA or Standard) 1 µl ~1000 ng/reaction 
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Table 2.19 qPCR cycling parameters for ABI Prism 7500 fast real-time cycler 
Cycles Temp (°C)  Time Comment 










Data was analysed using ABI Prism software. Expression data were normalized to 
control SNORD49a expression. 
 
Table 2.20 miRNA target sequence 










2.11. Data analysis 
GraphPad Prism 5.0 (GraphPad software) was used for statistical analysis. Data 
(Mean ± SEM) were analysed by one-way ANOVA followed by Dunnett’s post hoc 
test, Student’s unpaired t-test or Kruskal-Wallis test where appropriate. Significance 
was considered at p<0.05. 
 










3. Results I  
















In recent years, several dietary factors that affect non-haem iron absorption from 
foods have been identified. Human studies usually involve single test meals 
extrinsically tagged with radioactive iron (Cook et al. 1972). Through use of this 
method, it has been shown that single meals containing high amounts of polyphenols 
inhibit non-haem iron bioavailability (Samman et al. 2001, Reddy et al. 2000). 
Although this method allows investigators to control a number of variables, there are 
questions over its relevance. There appear to be discrepancies between single meal 
studies and long-term studies where a more varied diet is in place. For example a 
pronounced inhibition of iron by polyphenols has been observed in single-meal human 
studies but this effect has not been noted in longitudinal studies where consumption of 
high levels of polyphenols occurs over a long period of time. In a review of the related 
literature specific to polyphenols in black tea on iron absorption, it was suggested that 
moderate tea drinking, and thus a consistent intake of polyphenols was unlikely to 
have an adverse effect on iron status in healthy adults (Nelson and Poulter 2004).  
 
A characteristic feature of quercetin and its metabolites is its slow elimination with 
reported half-lives ranging from 11 to 28 hours (Manach et al. 2005) which means 
repeated and regular intakes could lead to plasma accumulation. This long-term effect 
would cause plasma levels of quercetin to exceed those achieved in single meal 
studies.  
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The aim of this first section was to bridge the existing gap between short-term and 
long-term effects of polyphenols on intestinal non-haem iron absorption. Quercetin 
was chosen as the polyphenol of choice due to its dominance in the diet and the Caco-
2 cell model was used.  
 
Caco-2 cells originate from human colon adenocarcinoma cells (Fogh et al. 1977) and 
are frequently used as an in vitro intestinal cell model. As cells differentiate, they 
polarize to develop apical and basolateral membrane, exhibiting a clearly defined 
apical brush border and tight intracellular junctions (Peterson and Mooseker 1992). 
Upon confluence, they form a monolayer, allowing transport of nutrients from the 
apical to the basolateral membrane making it a useful model to study intestinal 
nutrient and chemical transport. The TC7 clone used in this study is derived from a 
higher passage (p198) (Chantret et al. 1994) and is more morphologically 
characteristic of enterocytes and its transporters than the parental cell line. 
 
As the small intestine is the primary site of iron absorption, using an in vitro model 
allowed us to inspect intestinal iron transport in more detail and make changes in 
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3.2. Quercetin decreased 55Fe efflux 
 
Caco-2 cells were grown on Transwell inserts, with the use of differential pH to 
achieve transepithelial gradient and recognition of apical (pH 6.5) and basal (pH 7.5) 
membranes. For acute effects, quercetin was added along with 
55
Fe to the apical 
compartment and incubated for 20 minutes for uptake and 120 minutes for transport. 
For chronic effects, cells were pre-incubated with quercetin for 24 hours, after which 
the media was replaced with buffer containing 
55
Fe alone and subjected to uptake (20 
min) and transport (120 min) measurements. Cell lysates were used to measure protein 
concentration using the Bio-Rad method previously described and uptake and 
transport measurements were corrected to their corresponding protein levels. 
 
In the acute setting, quercetin caused a significant dose-dependent increase in iron 
uptake (p<0.05; Figure 3.1). However, during chronic conditions, where cells were 
exposed to quercetin for 24 hours, this effect was largely abrogated with no significant 
differences being noted. Conversely, quercetin caused a dose-dependent decrease in 













































Figure 3.1 Effect of quercetin on 
55
Fe bioavailability in Caco-2 cells 
Fully differentiated Caco-2 cells grown on Transwell inserts were treated with 1, 10 or 100 
µM quercetin for (A) 20 min or (B) 24 hours. Apical uptake of iron was measured after 20 
min and basolateral release of iron was measured after 120 min. All data was normalised to 
protein concentration. Data analysed by one-way ANOVA and Dunnett’s posthoc test 
compared to untreated control group; significance was determined at (*) p<0.05. Data 
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3.3. Quercetin induces down regulation of basolateral iron transporter mRNA 
expressions 
 
With the previous functional experiments showing that quercetin decreased iron efflux 
rather than iron uptake, we next investigated the molecular mechanism underpinning 
these effects. We started by looking at messenger RNA (mRNA) expression of genes 
controlling intestinal iron absorption. In particular this included duodenal cytochrome 
b (Dcytb) and divalent metal transporter 1 (DMT1) found on the apical membrane, 
responsible for iron uptake and ferroprotin and hephaestin which are found on the 
basolateral membrane responsible for transporting iron out of the cell.  
 
Caco-2 cells were treated with quercetin (0, 0.1, 1, 10 and 100 µM) 24 hours, 
followed by RNA isolation and quantitative-PCR to measure changes in expression. 
Dcytb mRNA showed no significant change with quercetin treatment; however an 
increasing trend could be noted (Figure 3.2). DMT1 expression was not significantly 
altered by exposure to any of the quercetin concentrations. 
 
Quercetin caused downregulation of ferroportin, significant at 10 µM (0.47 ± 0.17; 
p<0.05) and 100 µM (0.12 ± 0.04; p<0.001; Figure 3.2). Its partner hephaestin also 
exhibited a dose dependent-decrease, again significant at 10 µM (0.36 ± 0.09; 
p<0.001) and 100 µM (0.29 ± 0.04; p<0.001). Therefore it was understood that the 
gene expression of the apical transporters remained unaffected by quercetin treatment 
whereas the basolateral transporters were down regulated.  
  






















Figure 3.2 Dose-response effect of quercetin on mRNA expression of four important 
genes involved in intestinal iron transport 
Caco-2 cells were treated with quercetin (0-100 µM) for 24 hours. Changes in mRNA 
expression of (A) Dcytb n=9; (B) DMT1 n=9; (C); ferroportin n=14 (100 µM n=7) and (D) 
hephaestin n=8 (100 µM n=5) were measured by q-PCR. Data was normalised to control. 
Data analysed by one-way ANOVA and Dunnett’s posthoc test compared to untreated control. 
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3.4. Quercetin significantly decreases ferroportin protein expression 
 
To determine whether there were any functional consequences of ferroportin mRNA 
down regulation, we proceeded to examine the effects of quercetin on the protein 
expression of the two main iron transporters DMT1 and ferroportin. 
 
Cells were treated with quercetin (0 - 10 µM) for 24 hours. Thereafter cells were lysed 
and protein isolated and quantified. β-actin was measured as a housekeeping control. 
Films of western blots were scanned and semi-quantified using ImageJ software.  
 
The protein expression of DMT1 showed no change following exposure to quercetin. 
Ferroportin expression however, was significantly reduced in the presence of 10 µM 
quercetin (p<0.05; Figure 3.3). 
 
This protein data validated that quercetin does not affect DMT1, either at the gene or 
protein level, but quercetin does decrease ferroportin mRNA expression and this effect 





























Figure 3.3 Quercetin had no effect on DMT1 protein levels but decreased ferroportin 
protein levels 
Caco-2 cells were treated with quercetin (0-10 µM) for 24 hours followed by cell lysis and 
protein isolation. A representative western blotting band for each treatment is shown for (A) 
DMT1 n=6 and (B) ferroportin n=9. Blots were semi-quantified using Image J software. All 
results were normalised to β-actin and control group. Data analysed by one-way ANOVA and 
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3.5. Effects of quercetin on ferritin and IRP2 
 
Next we addressed the mechanism by which quercetin affects ferroportin expression. 
As quercetin is a known iron-chelator, we investigated whether quercetin was 
affecting the iron status of cells. We used ferritin and IRP2 as biomarkers of cellular 
iron content. 
 
3.5.1. Quercetin decreased ferritin protein levels 
Caco-2 cells were treated with 0, 0.1, 1, 10 µM quercetin for 24 hours. Cells were 
lysed and protein isolated and quantified. Changes in ferritin were measured using a 
colorimetric ELISA assay and readings were normalised to corresponding protein 
levels (Spectro-ferritin kit ATI Atlas Ltd UK, Cat No S-22).  
 
 
We found that with increasing concentrations of quercetin (0-10 µM), ferritin levels 
decreased, and were significantly lower than control values in cells exposed to 1 and 























Figure 3.4 Quercetin decreased ferritin protein levels 
Caco-2 cells were treated with quercetin (0-10 µM) for 24 hours followed by cell lysis and 
protein isolation. Ferritn was quantified using a colorimetric ELISA kit. Results were 
normalised to corresponding protein levels and control group. Data analysed by one-way 
ANOVA and Dunnett's post-hoc test compared to control group. N=15. Data presented as 
mean ± SEM. 
 
3.5.2. Effects of quercetin and FAC on IRP2 protein levels 
Caco-2 cells were treated with 0 - 100 µM quercetin, 50 µM ferric ammonium citrate 
(FAC) or quercetin and FAC combined for 24 hours. Cells were lysed and protein 
isolated and quantified. IRP2 protein was measured by the western blotting detection 
system. 
 
Quercetin at 100 µM produced a modest non-significant increase of IRP2 level (Figure 
3.5), whereas 50 µM ferric ammonium citrate (FAC) produced a slight decrease which 
could be recovered by 10 µM quercetin. FAC (50 µM) combined with 100 µM 






















































Figure 3.5 Effect of quercetin and FAC on IRP2 protein levels 
Caco-2 cells were treated with quercetin (0-100 µM) or FAC (50 µM) or in combination for 
24 hours. A representative band is shown. Blots were semi-quantified using Image J software. 
All results were normalised to β-tubulin and control group. Data analysed by one-way 
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3.5.3. Quercetin increased nuclear Nrf2 protein levels 
Quercetin is a powerful free radical scavenger, able to prevent or delay conditions 
which favour cellular oxidative stress. Nrf2 is a transcription factor that functions as a 
key inducer of antioxidant and detoxifying enzymes. Nrf2 regulatory effect on FPN 
and contribution to the cellular antioxidant defense system has not yet been looked at 
in intestinal cells. We postulated that quercetin may regulate intestinal ferroportin 
expression via Nrf2. 
 
Fully differentiated intestinal Caco-2 cells were treated with different concentrations 
of quercetin 0 – 100 µM (encompassing those concentrations used in the above 
studies) for 24 hours, followed by protein isolation. We looked at Nrf2 proteins in 
both cytosolic and nuclear preparations. To separate and extract each fraction NE-PER 
Nuclear and cytoplasmic Extraction Reagent (thermo Scientific Cat No 78833) kit was 
used.  
 
We found that there was no change in cytosolic levels of Nrf2 with quercetin 
treatment (Figure 3.6). In contrast, the nuclear component showed a dose-dependent 











































Figure 3.6 Quercetin increased nuclear Nrf2 protein levels 
Caco-2 cells were treated with quercetin (0-10 µM) for 24 hours followed by extraction of 
cytosolic and nuclear fractions. A representative band is shown for (A) cystosolic and (B) 
nuclear fractions. Blots were semi-quantified using Image J software. All results were 
normalised to β-actin and control group. Data analysed by one-way ANOVA and Dunnett’s 
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3.6. Erythropoietin (Epo)  
 
Erythropoietin (Epo) is a glycoprotein hormone produced by the kidneys in response 
to hypoxia, to meet body demands of increased erythropoiesis. There has been work to 
show that Epo may have direct effects on intestinal iron absorption (Srai et al. 2010) 
as Epo treatment induced up-regulation of iron transporters DMT1 and ferroportin and 
as such increased iron transport across Caco-2 monolayers. Epo activates many 
different signalling pathways to regulate iron homeostasis. Of particular interest for 
this study was the PI3K (phosphatidylinositol 3-Kinase) pathway which is an 
important modulator of gene expression and regulates a number of cellular responses.  
Specific inhibitors of the PI3K pathway have structurally similar properties to 
quercetin. We therefore wondered whether quercetin might influence Epo stimulation 
of iron transporter expression via as similar mechanism.  
 
3.6.1. Effects of Epo and PI3K inhibitor 
Caco-2 cells were grown on 12-well plates and treated for 24 hours on day 16 of cell 
culture growth. Cells were exposed to either Epo (1 Unit/ml), quercetin (10 or 100 
µM) and Epo in combination, PI3K inhibitor (20 µM: LY (2-(4-Morpholinyl)-8-
phenyl-4H-1-benzopyran-4-one), and Epo and PI3K inhibitor in combination. The 
four main genes in iron transport were looked at. 
 
  




Dcytb mRNA expression was not significantly altered by treatment with Epo (Figure 
3.7A). Co-incubation of Epo and quercetin (10 and 100 µM) as well as Epo and PI3K 
inhibitor also had no significant effect. 
 
DMT1 
Treatment with Epo non-significantly increased (2.2 fold from control) DMT1 
expression (Figure 3.7B). This rise caused by Epo was reduced almost back to control 
levels with addition of either 10 or 100 µM quercetin. PI3K inhibitor decreased 
DMT1 expression below basal level. 
 
Ferroportin 
Epo significantly increased ferroportin mRNA expression (p<0.05; Figure 3.7C). Co-
incubation of Epo with quercetin returned ferroportin expression back to basal levels. 
A similar effect was seen when Epo was incubated with PI3K inhibitor. 
 
Hephaestin 
Epo has no effect on hephaestin expression (Figure 3.7D) and treatment with Epo + 
quercetin (10 and 100 µM) did not alter hephaestin levels compared with control. 
PI3K inhibitor reduced hephaestin expression but this was not significant.   
  






















Figure 3.7 Effects of Epo and PI3K inhibitor on genes involved in iron transport 
Caco-2 cells were treated with quercetin (10 or 100 µM), Epo (1 U/ml) or PI3K inhibitor (20 
µM) alone or in combination for 24 hours. Changes in mRNA expression of (A) Dcytb n=6; 
(B) DMT1 n=8; (C); ferroportin n=10 and (D) hephaestin n=4. Data was normalised to 
control. Data analysed by one-way ANOVA and Dunnett’s post-hoc test compared to 
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3.7. Ferroportin promoter 
 
As a result of alternative splicing there are two possible isoforms of ferroportin that 
can arise – one which has an IRE in the 5’ UTR named FPN1A and one which lacks 
this IRE named FPN1B (Zhang et al. 2009). To investigate whether quercetin affects 
the ferroportin promoter and thereby ferroportin gene expression, both these 
transcripts were transiently transfected in Caco-2 cells.  
 
FPN1A promoter is 895 base pairs (bp) in size starting 845 bp before the transcription 
initiation site (just after exon 1b) and 50 bp after the initiation site. FPN1B promoter is 
1050 bp starting 1000 bp before the FPN1B transcription initiation site to 50 bp after 
the initiation site. These promoters were cloned into a pGL4 luciferase vector via 
XhoI/Hind III sites. 
 
3.7.1. Control studies for transfection efficiency and determining quercetin 
concentration 
First, transfection efficiency was measured. This was to ensure that the promoter was 
correctly inserted and driving firefly luciferase expression. FPN1A caused over a 90-
fold increase in luciferase activity compared to an empty, promoter-less pGL4 vector ( 
Figure 3.8) (p<0.0001). FPN1B caused a significant 4-fold increase compared to empty 















Figure 3.8 Comparison of promoter activities between empty vector and FPN pGL4 
Caco-2 cells were incubated for 24 hours after transfection and harvested for Luciferase assay. 
Data analysed by t-test compared to empty pGL4 vector. Significance: **** p<0.0001; n=3; 
data presented as mean ± SEM. 
 
 
Next we looked at the optimal concentration of quercetin to use in our studies. There 
was no significant difference in luciferase activity between empty pGL4 and pGL4 co-
treated with 10 µM of quercetin (Figure 3.9). However, there was a significant 
decrease caused by 100 µM quercetin (p<0.05). Therefore 100 µM quercetin 











































































































Figure 3.9 Quercetin 100 µM affects basal luciferase activity 
Caco-2 cells were incubated 24 hours after transfection and treated with quercetin (10 or 100 
µM) for a further 24 hours. Data analysed by one-way ANOVA and Dunnett’s post-hoc test 
compared to pGL4 alone. Significance: * p<0.05; n=3. Data presented as mean ± SEM. 
  
 
3.7.2. Effects of iron and quercetin on FPN1A and FPN1B promoter 
To examine the response of the different promoter constructs to iron loading and iron 
depletion, Caco-2 cells were transiently transfected with the promoter-containing 
plasmids for 24 hours. Media was then replaced and cells were treated with quercetin 
(1 or 10 µM), FAC (50 µM ferric ammonium citrate) or FAC and quercetin (10 µM) 
combined.  
 
There was no significant effect of quercetin treatment on either FPN1A or FPN1B 
promoter activity (Figure 3.10). Addition of FAC alone and together with quercetin 


















































Figure 3.10 Quercetin and FAC had no affect on FPN1A/1B promoter activities 
Caco-2 cells were incubated 24 hours after transfection and treated with quercetin (1 or 10 
µM), DFO (100 µM) and/or FAC (50 µM) for a further 24 hours. Data was normalised to 
untreated transfection control (either FPN1A or FPN1B alone). Data analysed by one-way 




3.7.3. Effects of Epo on FPN1A and FPN1B promoter 
As Epo was previously shown to stimulate FPN mRNA expression we wanted to see 
what effect it would have on the ferroportin promoter activity and whether quercetin 
(10 µM) would affect the Epo response. 
 
Epo had no effect on FPN1A activity but significantly increased FPN1B promoter 
activity (p<0.01; Figure 3.11). Co-treatment with quercetin did not diminish the 



















































































































Figure 3.11 Epo increased FPN1B activity but had no effect on FPN1A 
Caco-2 cells were incubated 24 hours after transfection and treated with quercetin (10 µM), 
Epo (1U/ml) or Epo + quercetin for a further 24 hours. Data was normalised to untreated 
transfection control (either FPN1A or FPN1B alone). Data analysed by one-way ANOVA and 
Dunnett’s post-hoc test. Significance: * p<0.05 **p<0.01; N=3 (FPN1A, FPN1B, Q10 and 
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3.7.4. Effects of HIF1α and HIF2α inhibitors on promoter activity 
Hypoxia inducible factors (HIFs) are transcription factors that can regulate the 
transcription of ferroportin. They are formed by an oxygen sensitive α subunit 
(HIF1α/HIF2α) and a constitutively expressed β subunit. To examine the effects of 
HIFs on basal ferroportin promoter activity, specific HIF1α (20 µM) and HIF2α (10 
µM) inhibitors were used to block this oxygen-sensitive pathway. HIF inhibitors were 
also co-incubated with quercetin (10 µM). 
 
FPN1A 
There was no significant effect of either the HIF1α or the HIF2α inhibitor on FPN1A 
promoter activity (Figure 3.12). Co-incubation of HIF1α inhibitor with quercetin (10 
µM) significantly decreased FPN1A promoter activity (p<0.01) whereas no significant 
effect of quercetin was noted with the HIF2α inhibitor. 
 
FPN1B 
Neither HIF1α inhibitor nor HIF2α inhibitor had an effect on FPN1B promoter 
activity (Figure 3.13). In contrast to FPN1A, co-incubation of either HIF inhibitor with 
quercetin (10 µM) had no effect on FPN1B. This suggests that HIFs use FPN1A 
promoter rather than FPN1B to exert their regulatory effects. 
 
  












Figure 3.12 Co-treatment of HIF1α inhibitor and quercetin decreased FPN1A activity 
Caco-2 cells were incubated for 24 hours after transfection and treated with HIF1α inhibitor 
(20 µM), HIF2α inhibitor (10 µM) either alone or together with quercetin (10 µM) for 24 
hours. Data was normalised to untreated control (FPN1A alone without any treatment). Data 
analysed by one-way ANOVA and Dunnett’s post-hoc test. Significance: **p<0.01 

















Figure 3.13 HIF1α/ HIF2α inhibitors have no effect on FPN1B promoter activity 
Caco-2 cells were incubated for 24 hours after transfection and treated with HIF1α inhibitor 
(20 µM), HIF2α inhibitor (10 µM) either alone or together with quercetin (10 µM) for 24 
hours. Data was normalised to untreated control (FPN1A alone without any treatment). Data 
analysed by one-way ANOVA and Dunnett’s post-hoc test. Significance: **p<0.01 
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3.7.5. Effect of quercetin on FPN1A and FPN1B mRNA expression 
To investigate whether quercetin was affecting one transcript over another, Caco-2 
cells were treated with increasing doses of quercetin (0, 1, 10, 100 µM). Changes in 
gene expression were measured by q-PCR using specific primers for FPN1A and 
FPN1B. 
 
FPN1A exhibited a dose-dependent decrease with increased quercetin concentrations 
(100 µM: 0.3 ± 0.06 p<0.05; Figure 3.14). On the other hand, quercetin increased 






Figure 3.14 Quercetin decreased FPN1A mRNA and increased FPN1B mRNA 
Caco-2 cells were treated with quercetin (0-100 µM) for 24 hours. Changes in mRNA 
expression of FPN1A (n=9) or FPN1B (n=4) were measured by q-PCR. Data was normalised 
to housekeeping 18S and control. Data analysed by one-way ANOVA and Dunnett’s posthoc 
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3.8. MicroRNA (miRNA) 
 
Given the importance of FPN, it is not surprising that its regulation occurs at multiple 
levels. MicroRNAs (miRNAs) present a novel mechanism of post-transcriptional 
regulation, independent of IRP/IRE regulation that occurs at the 5’UTR of FPN. 
miRNAs are small endogenous non-coding RNA that bind to complementary 
sequences in the 3’UTR of target mRNA, usually resulting in mRNA degradation or 
translational repression.  
 
Iron status is a factor that appears to affect many miRNAs. A recently published paper 
found that miR-485-3p in particular, may regulate FPN by directly targeting FPN 
3’UTR (Sangokoya et al. 2013). This microRNA was induced during iron deficiency 
and repressed FPN protein expression in HepG2 (hepatocyte) and K562 (human 
erythroid) cell lines. This provided evidence that miRNAs are capable of regulating 
FPN expression.    
   
Having looked at FPN 5’UTR, it was interesting to see what effect quercetin would 
have on FPN 3’UTR. We began this investigation by carrying out miRNA arrays on 
quercetin-treated samples to screen for quercetin-induced miRNA changes in Caco-2 
cells. We identified a number of miRNAs that were regulated by quercetin. Table 3.1 
shows those that were upregulated by at least 1.5-fold as compared to control. 
 
  
  5. Results III 
 
120 









Results from the chip were filtered to show human miRNA only and true significant changes 
(p<0.05) when compared to control.   
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3.8.1. miRNA validation via q-PCR 
We selected 5 different miRNAs that bioinformatics site (http://www.targetscan.org) 
predicted may target mRNA of genes associated with iron metabolism. We attempted 
to validate these with q-PCR which is a more sensitive measure, to see if changes 
were produced. The following miRNAs were selected: hsa-let-7a; hsa-let-7d; hsa-let-
7f; hsa-miR-106b; hsa-miR-92b.  
 
There were no significant differences in any of the miRNAs when tested by q-PCR 
between control and quercetin treated group (Figure 3.15A). This indicates that these 
particular miRNAs do not possess any complementary binding site for FPN mRNA. 
Figure 3.15B shows how q-PCR results compare with miRNA changes measured by 

































Figure 3.15 Quercetin has no effect on selected miRNAs 
Caco-2 cells were treated with quercetin (10 µM) or untreated (control) for 24 hours.  
(A) Changes in miRNA expression measured by q-PCR (n=8). (B) Changes in miRNA from 
array compared to q-PCR. Data normalised to corresponding control for both methods. Data 
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3.8.2. Transfection of 3’UTR ferroportin construct 
Interactions of miRNAs with their target mRNAs may be key in gene regulation but 
currently very little experimental data is available. There is a large dependence on 
computational predictions but the lack of experimental data means the algorithms used 
may not be the most accurate. 3’UTR reporter constructs have been used by many 
researchers as a method to validate interactions between miRNAs and their potential 
targets. In this study we used a ferroportin 3’UTR-luciferase reporter clone to assay 
for endogenous miRNA activity. Pre-cloned human ferroportin 3’UTR was inserted 
into a viral vector which expressed an optimised luciferase reporter gene (Renilla). 
After 24 hours transient transfection differentiated Caco-2 cells were either left 
untreated or treated with quercetin (10 µM) for a further 24 hours. Results were 
normalised to untreated empty vector.  
 
Transfection with 3’UTR significantly increased renilla activity (Figure 3.16; 12.24 ± 
0.95; p<0.001) confirming transfection had correctly taken place and the 3’UTR was 
driving renilla reporter expression. Co-incubation of 3’UTR with 10 µM quercetin 
was still significantly increased compared to control (9.21 ± 1.35 p<0.01) but there 
was a reduction in renilla activity when compared to 3’UTR alone suggesting that 





















Figure 3.16 Quercetin decreased FPN 3’UTR induced renilla activity 
Caco-2 cells were transfected with ferroportin (FPN) 3’UTR containing reporter plasmid for 
24 hours or an empty vector (control). 3’UTR cells were treated with quercetin (10 µM) for 24 
hours. Data normalised to control renilla levels. Data analysed by one-way ANOVA and 
Tukey’s posthoc test. Data presented as mean ± SEM; n=3.  
 
3.8.3. Quercetin significantly upregulated hsa-mR-17-3p 
There is compelling evidence that hsa-miR-485-3p can regulate FPN (Sangokoya et 
al. 2013). Bioinformatics suggested that hsa-miR-17 might also target FPN; this 
miRNA was upregulated in our miRNA arrays (hsa-miR-17-5p: 1.19; hsa-miR-17-3p: 
1.54) and hsa-miR-17-3p presents least four possible binding sites. Predicted potential 


















































Figure 3.17 Predicted miRNA binding sites to ferroportin 3’UTR sequence 
 
 
To investigate whether quercetin has a regulatory effect on these miRNAs, we isolated 
miRNAs from Caco-2 quercetin-treated samples and carried out q-PCR to check 
expression levels.  
 
Quercetin induced over 100-fold increase in hsa-miR-17-3p expression compared to 
control (101.0 ± 25.1; p<0.01; Figure 3.18). Expression of hsa-miR-17-5p and hsa-


































Figure 3.18 Quercetin significantly increased hsa-miR-17-3p expression 
miRNA was isolated from Caco-2 cells previously treated with quercetin (10 µM) or untreated 
(control) for 24 hours. Changes in expression measured by q-PCR (A) hsa-miR-17-3p (n=5) 
(B) hsa-miR-17-5p (n=6) and (C) hsa-miR-485-3p (n=6). Data normalised and compared to 
























































































The primary site controlling body iron levels is the small intestine which determines 
dietary iron absorption. Iron uptake is regulated by a number of factors and the human 
intestinal Caco-2 cell line provides a useful and convenient model to look in much 
greater detail at how individual components of the diet influence absorption. 
 
We utilised the Caco-2 model to investigate the short-term and long-term effects of 
polyphenols on iron absorption. Polyphenols are generally thought to have an 
inhibitory effect on iron transport due to their properties as iron chelators (Afanas'ev 
et al. 1989). However, we found that in an acute setting (20 min), the most abundant 
dietary polyphenol, quercetin, significantly increased iron uptake. Similar findings 
were observed in previous studies using grape seed polyphenols (Kim et al. 2008). 
Grape seed extract and EGCG (epigallocatechin-3-gallate) acted as reducing agents 
favouring Fe
2+
. Also Vlachodimitropoulou et al (2010) showed that quercetin could 
substitute for ascorbate as an electron donor to Dcytb, leading to reduction of iron to 
the absorbable ferrous form. It was also shown that quercetin could enter cells via 
GLUT-transporters (Vlachodimitropoulou et al. 2011). This provides a possible 
system for quercetin-Fe complexes to gain cellular access. Despite an increase in iron 
uptake, efflux following acute exposure to quercetin was decreased. This suggests the 
formation of intracellular quercetin-Fe complexes that are too large to be exported via 
FPN or direct inhibition of intracellular quercetin on the FPN transporter. Further 
studies are required to determine mechanisms. 
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Following longer-term exposure (24 hours), quercetin no longer had an effect on 
uptake but significant reduction of iron efflux was maintained. The data agrees with 
observations where single-meal studies show a significant reduction in iron absorption 
but individuals with long-term polyphenol intakes have no such effect (Samman et al. 
2001, Reddy et al. 2000). 
 
Polyphenols present in fruit and vegetables have long been associated with numerous 
health benefits (Hertog et al. 1993a) and this is often attributed to their antioxidant 
properties as chelators (Morel et al. 1993) and free radical scavengers (Zhao et al. 
2001). However, further studies have now demonstrated that polyphenols can 
additionally modify gene expression. In the Caco-2 model, cDNA array analysis 
revealed that incubation with polyphenols epicatechin and cocoa extract altered the 
expression of over 40 genes (Noe et al. 2004). Changes in the expression of STAT1, 
MAPKK1 and ferritin genes were validated by q-PCR and western blotting. These 
genes, which are involved in the cellular response to oxidative stress, are in 
accordance with the antioxidant properties of polyphenols but also imply mechanisms 
of action at the molecular level. Microarray data of HUVEC cells (human umbilical 
vein endothelial cells) show that quercetin modifies a significant number of genes 
(Nicholson et al. 2008). Notas et al (2012) showed that 24 hour incubation of HepG2 
cells with quercetin modified transcription and/or activity of a large number of 
transcription factors thereby affecting gene expression (Notas et al. 2012). Therefore 
to explain our results of how 24 h quercetin treatment significantly reduces iron export 
without affecting uptake, the gene expression of iron transporters was investigated. 
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Here we showed that DcytB and DMT1 mRNA were not significantly changed by 
quercetin treatment but there was a significant down-regulation in  mRNA expression 
of basolateral transporter ferroportin, and its partner ferroxidase hephaestin. These 
observations provide a cellular mechanism that is consistent with the effects seen in 
the 
55
Fe transport studies. These changes were validated at the protein level which had 
a mirrored response to mRNA of quercetin having no effect on DMT1 protein but a 
down-regulation of ferroportin protein levels. Taken together, the data creates a 
working model that quercetin acutely chelates iron which stimulates similar cellular 
responses as to an iron deficiency condition, causing enterocytes to increase iron 
uptake. After the initial bout, the system recovers and with time adapts so that a 
significant influx of iron is no longer required but cellular iron content is tightly 
controlled at the export level.  
 
To further explore the hypothesis that quercetin may be inducing a state of cellular 
iron deficiency, we assessed the iron status of the cell by looking at ferritin and IRP2 
protein as iron status biomarkers. Ferritin is a ubiquitous intracellular iron storage 
protein (Harrison and Arosio 1996) and the amount of ferritin stored usually reflects 
the amount of iron stored. Ferritin mRNA contains an IRE in its 5’UTR (Hentze et al. 
1987). High or adequate levels of iron induce the degradation of IRP2 but during low 
levels of iron, binding of IRP2 to the IRE prevents translation of ferritin so less 
protein is produced. Following incubation with quercetin, ferritin protein was 
significantly decreased suggesting a lack of iron availability within the cell. Quercetin 
had no effect on IRP2 which is interesting because if quercetin was indeed causing 
iron deficiency we would expect an increase in IRP2. Also if the cell was iron 
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deficient, we would expect an increase in DMT1 (Zoller et al. 2001) and ferroportin 
(McKie et al. 2000) to enhance iron absorption. Therefore, although this mechanism 
might contribute to some of the effects seen in the acute condition, it is unlikely to be 
a main factor in the observed ferroportin down-regulation. Some other mechanism(s) 
must also be in play.  
 
We began the search by investigating Nrf2. This transcription factor has recently 
received attention due to binding sites for it having been found on the macrophage 
ferroportin promoter (Marro et al. 2010). Further linking it to our study, it has been 
suggested that quercetin may regulate Nrf2 (Granado-Serrano et al. 2012). To see if 
this was the crucial link between the quercetin-iron-ferroportin axis, we looked at 
cytosolic Nrf2 protein and translocated nuclear Nrf2 protein in Caco-2 cells. The 
cytosol showed no change but the nuclear fraction showed a significant increase in 
Nrf2 protein with increasing quercetin concentration (100 µM: p<0.001). This is not 
consistent with our observations. As a transcription factor, Nrf2 binds to promoter 
regions to induce gene expression thus if quercetin increases nuclear Nrf2 then this 
should increase ferroportin expression. Interestingly, Granado-Serrano et al. (2012) 
showed that while 10 µM quercetin significantly increased nuclear translocation of 
Nrf2 in HepG2 cells, 50 µM quercetin inhibited this effect; our results in Caco-2 cells 
do not show this biphasic response. 
 
Different kinases have been reported to regulate Nrf2 including ERK and PI3K and 
phosphorylation of Nrf2 appears to be essential for its nuclear translocation (Eggler et 
al. 2008, Granado-Serrano et al. 2012). As quercetin seems to increase nuclear Nrf2 
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but contradictorily decrease FPN expression, it could be an antioxidant effect of 
quercetin to modulates these kinases to affect Nfr2 rather than having a direct effect. It 
is likely that quercetin-induced Nrf2 changes are cell specific but in Caco-2 cells our 
results show it is unlikely to be the main regulatory mechanism in controlling 
ferroportin expression.   
 
We then moved our attention to erythropoietin (Epo) which is known to stimulate 
DMT1 and FPN (Srai et al. 2010). We confirmed that Epo does indeed stimulate 
DMT1 and FPN and showed that quercetin is able to counteract Epo-induced 
stimulation on DMT1 and FPN by reverting it to basal levels (Figure 3.7). This 
suggested that quercetin was affecting FPN expression by an Epo-stimulatory 
pathway. We focused on the PI3K (phosphatidylinositol 3-Kinase) pathway as 
specific PI3K inhibitors have similar structural properties to quercetin ((Vlahos et al. 
1994). We found that incubation with the PI3K inhibitor LY294002 inhibited the 
stimulatory effect of Epo on DMT1 and FPN. Interestingly, the PI3K inhibitor 
reduced DMT1 mRNA below control level suggesting that it might be an essential 
pathway required for basal DMT1 expression; the lack of effect of quercetin on 
DMT1 mRNA suggests that it does not operate via PI3K signalling. However in the 
future it would be wise to look at phospho-Akt, a downstream target of the PI3K 
pathway. Epo increases phosphorylation of the Akt protein (Shi et al. 2010, Ratajczak 
et al. 2001) and if this phosphorylation was blocked by quercetin and the PI3K 
inhibitor then it would confirm that they both work by the same pathway.  
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A recent paper by Zhang et al. (2009) showed that that there are two isoforms of 
ferroportin which are different in their 5’UTR promoter regions: FPN1A (+IRE) and 
FPN1B (-IRE). These isoforms are differentially regulated by iron. Having cloned the 
promoters into expression vectors, we were surprised to find that in Caco-2 cells 
neither iron (ferric ammonium citrate (FAC)) nor quercetin treatment had any effect 
on the activity of either promoter (Figure 3.10). However, at the mRNA level, 
quercetin did show differential effects on the two ferroportin isoforms – decreasing 
FPN1A but increasing the expression of FPN1B (Figure 3.14). This suggests that 
despite FPN1B being specific to intestinal epithelial cells, FPN1A remains the major 
isoform (Zhang et al 2009).  
 
Intestinal ferroportin expression is regulated by the hypoxia-inducible factor HIF2α 
(Taylor et al 2012). We investigated the effect of chemical inhibitors of both HIF1α 
and HIF2α on ferroportin promoter activity. While neither inhibitor altered basal 
promoter activity, co-incubation of HIF1α inhibitor with quercetin (10 µM) 
significantly decreased FPN1A+IRE promoter activity (p<0.01) suggesting that there 
may be some interaction between quercetin and the HIF1α pathway in regulating 
ferroportin expression.  
 
Since exposure to quercetin alone did not influence the activities of either promoter 
this suggests that there are no quercetin-responsive elements in the 895 (1A)/1050 
(1B) base pair proximal sequence of FPN that can account for quercetin inhibition of 
FPN. We therefore moved to investigate the 3’UTR of FPN, focusing on microRNA 
(miRNA) binding sites. 




miRNAs are small non-coding RNA molecules, usually of 21 to 25 nucleotides in 
length that negatively regulate gene expression (Wu et al. 2006). They are partially 
complementary to one or more mRNA molecule. miRNA research is an exciting new 
field which is constantly being updated. Since the early 2000, thousands of miRNAs 
have been discovered and the miRBase database (www.mirbase.org) hosted by the 
Sanger Institute, provides information on miRNA sequences and target prediction 
information. Recent evidence has shown that many miRNAs are activated by changes 
in iron status and specific miRNAs can regulate iron metabolism genes such as miR-
Let-7d for DMT1(-IRE) in erythroid cells (Andolfo et al. 2010) and miR-485-3p for 
FPN in hepatocyte and erythroid cells (Sangokoya et al. 2013). These findings 
highlight the exciting possibility that miRNAs can provide an additional means of 
post-transcriptional iron regulation. 
 
We carried out an Affymetrix GeneChip miRNA array to seek out miRNAs that were 
activated by quercetin treatment and from those chose to validate specific miRNAs 
that were significantly upregulated or cross-matched with the miRBase database as 
likely candidates involved in iron regulation. Amongst others (hsa-let-7a; hsa-let-7f; 
hsa-miR-106b; hsa-miR-92b. hsa-miR-17-5p; hsa-miR-17-3p), this included miR-let-
7d, miR-485-3p and miR-17-3p. Our results found that miR-17-3p was significantly 
activated and upregulated by quercetin treatment (Figure 3.18) suggesting that 
quercetin modulates this miRNA as a mechanism of decreasing intestinal FPN 
expression. FPN 3’UTR has a number of binding sites for this miRNA and the fact 
that both measures of array and q-PCR show significant upregulation of miR-17-3p 
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shows consistency and accuracy of this data. There was no significant change in q-
PCR analysis of miR-485-3p which also possesses potential binding sites on FPN 
3’UTR. This could be because some of these miRNAs are cell-specific and not 
expressed in enterocytes; for example although miR-485-3p had a regulatory effect on 
FPN in hepatocyte and erythroid cells (Sangokoya et al. 2013), it was not detected in 
our miRNA array which used Caco-2 cells, and it was not changed when measured by 
q-PCR. Quercetin did not affect DMT1 mRNA and as such also did not change miR-
let-7 family expression.  
 
Upregulation of miR-17-3p by quercetin shows a novel mechanism of FPN regulation 
in intestinal cells. These experiments should be repeated in other cell lines to assess 
cell-specificity. 
 
To confirm endogenous miRNA activity with its target 3’UTR-FPN, we transiently 
transfected Caco-2 cells with the ferroportin 3’UTR. 3’UTR increased reporter 
activity but quercetin (10 µM) caused a reduction in activity implying that quercetin is 
able to interfere with the miRNA-3’UTR interaction and thereby reduce reporter 
signalling. Overall, this suggests that quercetin can affect miRNA activity to regulate 
FPN. However, the diverse nature of miRNAs mean that one miRNA can have 
multiple mRNA targets and similarly a given target may be targeted by multiple 
miRNAs. Their expression and activity also varies greatly between different tissues. 
This makes it hard to narrow down miRNAs to a sole target or function. However, 
with reports of miRNA regulation of iron uptake (DMT1: miR-Let-7d ) (Andolfo et al. 
2010), storage (ferritin: miR-200b) (Shpyleva et al. 2011), export (ferroportin: miR-
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485-3p) (Sangokoya et al. 2013), and regulation (hepcidin: miR-122) (Castoldi et al. 
2011)  it is quite clear that miRNAs possess important regulatory roles. If the miRNA-
gene axis can be manipulated, it can be used as a therapeutic tool to treat various 
diseases. By using miRNA to target intracellular FPN, cellular iron status can be 
altered; hepcidin deficiency or resistance can be bypassed and therapeutic miRNA 
mimetics or inhibitors might be developed to target iron overload conditions. This 
research provides insight into the direct relationship between polyphenol-miRNA-
FPN interactions at the intestinal iron absorption stage. Although more work is 
required on miRNA biology, the prospect of miRNAs as future therapeutic targets 



































4. Results II 
HepG2 hepatocyte cell line 
  





4.1.1. Quercetin and hepcidin expression 
The liver is the primary site of iron storage and therefore contains a host of iron 
regulatory proteins to achieve this function. The aim of this part of the study was to 
investigate the effects of quercetin on hepatocytes. We used HepG2 cells as an in vitro 
model of human hepatocytes. HepG2 cells are of hepatocellular carcinoma origin 
(Knowles et al. 1980) and are adherent, epithelial-like cells which grow as monolayers 
and in small aggregates. Their robust morphology and their ability to secrete a range 
of major plasma proteins make them a good model for studying liver metabolism. 
 
The liver is also the site of hepcidin production. We focused on the transcriptional 
regulation of hepatocyte hepcidin expression as a number of putative transcription 
factor-binding sites have been identified in the hepcidin promoter including response 
elements for SMAD4 (Verga Falzacappa et al. 2008). SMAD4 is a co-SMAD protein 
that complexes with other receptor-regulated SMADs to serve as a transcription factor 
to activate the hepcidin promoter. Bone morphogenetic protein 6 (BMP6) is a key 
endogenous regulator of hepcidin (Andriopoulos et al. 2009). The critical role of the 
BMP6/SMAD pathway is highlighted in BMP6
-/-
 mice (Meynard et al. 2009) and in 
mice with targeted disruption of SMAD4 (Wang et al. 2005) where a loss of hepcidin 
expression is accompanied by a huge parenchymal iron overload - a phenotype similar 
to that seen in haemochromatosis. 
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4.1.2. Iron and HepG2 cell proliferation  
Iron is indispensable for DNA synthesis and deprivation can arrest cell proliferation 
because it is essential to many enzymes involved in cell division. One such enzyme is 
ribonucleotide reductase which is responsible for reducing ribonucleotides into 
deoxyribonucleotides for DNA synthesis. Ribonucleotide reductase contains an iron 
centre which is continually regenerated and is therefore sensitive to intracellular iron 
depletion; such depletion can inhibit ribonucleotide reduction, stop DNA synthesis 
and eventually cause cessation of cell growth (Nyholm et al. 1993). 
 
Rapidly dividing cancer cells express elevated levels of the iron transporter TfR1 
(transferrin receptor-1) to meet the high iron demand for rapid DNA synthesis 
(reviewed by Richardson et al. 2009). Iron chelating agents such as desferrioxamine 
have been shown to reduce the growth of tumour cells in vitro (Reddel et al. 1985). 
The chelator can cross plasma membrane to bind intracellular iron thereby limiting its 
bioavailability. Addition of iron to media is able to reverse the growth inhibition 
demonstrating that iron is the major cause of reduced proliferation (Fukuchi et al. 
1994, Nyholm et al. 1993). 
 
Quercetin is an iron chelator and some anti-proliferative effects have been 
demonstrated. 24-hour incubation with quercetin inhibited HeLa cell proliferation 
which was readily reversed by adding iron (Triantafyllou et al. 2007). However, in rat 
aortic smooth muscle cells, low concentrations of quercetin showed anti-proliferative 
effects whilst high quercetin concentrations induced the opposite effect of being pro-
proliferative. (Shih et al. 2004). 
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We used a range of iron concentrations in the form of ferric ammonium citrate (FAC) 
and hemin (to represent haem) to investigate what effect they would have on HepG2 
cell proliferation and whether quercetin would be able to block these effects through 
its chelating ability. 
 
4.1.3. HepG2 cell viability 
Studies have noted that quercetin is protective against various cancers by activating 
apoptotic pathways (Nguyen et al. 2004, Granado-Serrano et al. 2006). In human 
hepatoma HepG2 cells, it was shown that 18 hour incubation with quercetin 
significantly induced cell death (68% with 100 μM/L) (Granado-Serrano et al. 2006). 
However, this increase in cell mortality was both time- and dose-dependent. A shorter 
incubation time of 4 hours had no effect on cell viability and lower concentrations of 
quercetin (10 μM) showed evidence of pro-survival. Survival-signalling cascade in 
many cells involves cross-communication between PI3K-Akt and PI3K-ERKs. 
ERK1/2 requires continuous activation for cell survival and proliferation and it is 
proposed that inhibition of this by quercetin contributes to increased cell death. Low 
concentrations of quercetin (10 and 25 μM) however increase phosphorylation of 
ERK1/2 and Akt suggesting that survival of HepG2 cells is dependent on activation of 
cell-survival pathways most likely involving PI3K-Akt and ERK pathways (Granado-
Serrano et al. 2006, Mitsui et al. 2001). 
 
The influence of iron (FAC and haem), hepcidin and quercetin on HepG2 viability 
was measured using the colorimetric MTS assay. As the PI3K pathway is strongly 
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implicated in the regulation and survival of cells, we also examined the effect of a 
PI3K inhibitor on iron-induced viability. 
4.2. Results 
 
4.2.1. Effect of quercetin on gene expression of iron-related proteins 
We investigated the effect of quercetin on: DMT1, FPN, BMP6, SMAD4 and 
hepcidin. HepG2 cells were grown on 12-well plates for 24 hours and were treated 
with quercetin (0, 0.1, 1, 10 and 100 µM) for a further 24 hours. This was followed by 
RNA isolation and quantitative-PCR to measure changes in mRNA expression. 
 
Unlike in Caco-2, quercetin induced a significant and dose-dependent decrease in 
DMT1 expression (p<0.01; Figure 4.1). FPN, similar to Caco-2 was also significantly 
down-regulated. There was no significant effect of quercetin on BMP6 or SMAD4 
mRNA expression. However, hepcidin levels were increased significantly at 100 µM 



































Figure 4.1 Quercetin decreased DMT1 and FPN but increased hepcidin expression 
HepG2 cells were treated with quercetin (0, 0.1, 1, 10, 100 µM) for 24 hours. Changes in 
mRNA expression were measured by q-PCR. Data normalised to 18S. Data analysis by one-
way ANOVA and Dunnett’s posthoc compared to untreated control (0 µM). 
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4.2.2. Dose-response of FAC, haem, hepcidin and quercetin on cell proliferation 
HepG2 cells were grown in 96-well plates for 24 hours. Media was replaced and 
treatment added to cells, along with the BrdU label (Calbiochem, Cat No HTS01) for 
further 24 hour incubation. Cells were treated with FAC, haem (0, 10, 50, 100 μM), 
hepcidin (0, 0.01, 0.1, 1 µM) or quercetin (0, 1, 10, 100 μM). Thereafter the 
manufacturer’s protocol was followed to measure proliferation. 
 
FAC had no significant effect on HepG2 cell proliferation (Figure 4.2). Haem, 
however, increased proliferation, significantly at 50 and 100 μM (p<0.05). Hepcidin 
had no effect. Quercetin at 10 μM increased proliferation (1.62 ± 0.1; p<0.05) but at 

























Figure 4.2 Dose-responses of FAC, haem, hepcidin and quercetin on HepG2 
proliferation 
HepG2 cells were treated with FAC, haem (0, 10, 50, 100 μM), hepcidin (0, 0.01, 0.1, 1 µM) 
or quercetin (0, 1, 10, 100 µM) and BrdU for 24 hours. Proliferation was measured by 
fluorescent BrdU assay. Data normalised to positive control. Data analysis by one-way 
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4.2.3. Quercetin increased FAC-proliferation but decreased haem-proliferation 
To look at the effect of quercetin on FAC/haem-induced proliferation, increasing 
concentrations of quercetin (1, 10, 100 µM) or hepcidin (0.01, 0.1, 1 µM) were added 
to 30 µM FAC or haem (a set concentration of 30 μM gives consistency between the 












Figure 4.3 Quercetin increased proliferation with FAC 
HepG2 cells were treated for 24 hours with FAC or haem combined with quercetin (1, 10, 100 
µM) or hepcidin (0.01, 0.1, 1 µM) and BrdU. Data normalised to positive control. Data 
analysis by one-way ANOVA and Dunnett’s posthoc compared to FAC or haem alone. 
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Hepcidin, which is proposed to increase cell iron content by blocking ferroportin, did 
not affect cell proliferation in response to either FAC or haem challenge (Figure 4.3). 
Quercetin at 100 µM caused an inhibition of haem-induced proliferation by returning 
proliferation to basal levels (0.96 ± 0.07). Quercetin at 1 or 100 µM did not affect 
FAC response but 10 µM still significantly increased proliferation even in the 
presence 30 µM FAC (1.59 ± 0.02; p<0.01; Figure 4.3). 
 
4.2.4. PI3K inhibitor does not affect FAC-/haem-induced proliferation 
PI3 kinase (PI3K) is a molecule central to cellular growth, proliferation and survival. 
Work has shown that in some situations quercetin is capable of inhibiting PI3K 
activity (Hwang et al. 2009). In order to establish whether quercetin’s effects on cell 
proliferation were by inhibition of PI3K, a PI3K inhibitor (LY294002) was added to 
cells alongside FAC or haem. The PI3K inhibitor (20μM) was initially added alone to 
determine any baseline effects on cell proliferation, however, no significant difference 
was noted (Figure 4.4). 
 
PI3K inhibitor had no significant effect on either FAC or haem-induced proliferation 


































Figure 4.4 PI3K inhibitor has no significant effect on cell proliferation 
Cells treated for 24 hours with (A) PI3K inhibitor (20 µM) or in combination with (B) FAC or 
(C) haem (30 µM) and BrdU label. Data normalised to positive control. Data analysis by one-
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4.2.5. Dose-response of FAC, haem, hepcidin and quercetin on cell viability 
HepG2 cells were grown in 24-well plates for 24 hours. Media was replaced and 
treatment added to cells for another 24 hour incubation period. Cells were treated with 
FAC, haem (0, 10, 50, 100 μM), hepcidin (0, 0.01, 0.1, 1 µM) or quercetin (0, 1, 10 μM). 
The manufacturer’s protocol was followed to read absorbance at 485 nm as a measure 
of viability. 
 
FAC significantly decreased cell viability by approximately 50% at all concentrations 
(p<0.05; Figure 4.5). Haem, hepcidin and quercetin did not significantly alter cell 
viability. Quercetin at a concentration of 100 μM was not included in the analysis as 




























Figure 4.5 Dose-responses of FAC, haem, hepcidin and quercetin on HepG2 viability 
HepG2 cells were treated with FAC, haem (0, 10, 50, 100 μM), hepcidin (0, 0.01, 0.1, 1 µM) 
or quercetin (0, 1, 10 µM) for 24 hours. Viability measured by MTS assay. Data analysis by 
one-way ANOVA and Dunnett’s posthoc compared to untreated control (0 µM). 
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4.2.6. Quercetin does not affect viability with FAC or haem 
To study the effects of quercetin and hepcidin on FAC/haem-induced viability, 
increasing concentrations of quercetin (1, 10 µM) and hepcidin (0.01, 0.1, 1 µM) were 
added to 30 µM FAC or haem. FAC did not reduce cell viability when added with 
quercetin. Quercetin had no effect on haem. Hepcidin had no effect on FAC or haem-

















Figure 4.6 Quercetin has no effect on viability with FAC or haem 
HepG2 cells were treated for 24 hours with FAC or haem combined with quercetin (1, 10 µM) 
or hepcidin (0.01, 0.1, 1 µM). Data analysed by one-way ANOVA and Dunnett’s posthoc 
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4.2.7. PI3K inhibitor does not affect FAC-/haem-induced proliferation 
We used a PI3K inhibitor (LY294002 20 μM) to determine what effect it had on iron-
induced viability. This was added in combination with 30 μM FAC or haem to cells. 
The PI3K inhibitor was initially added alone to determine baseline effects on cell 
viability, however, no significant difference was noted (Figure 4.7 top panel). 
 
PI3K inhibitor had no significant effect on either FAC or haem induced viability when 






























































Figure 4.7 PI3K inhibitor has no significant effect on cell viability 
Cells treated for 24 hours with (A) PI3K inhibitor+ (20 µM) or in combination with (B) FAC 
or (C) haem (30 µM). Data analysed by one-way ANOVA and Dunnett’s posthoc compared 




























































































4.3.1. Iron metabolism gene expression 
The liver is a very important organ for iron metabolism. Not only is it the main site of 
iron storage but it also produces hepcidin, often regarded as the master regulator of 
iron homeostasis (Drakesmith and Prentice 2012). Hepatic hepcidin synthesis is 
stimulated by high levels of systemic iron (Pigeon et al. 2001). Binding of hepcidin to 
FPN causes FPN degradation which prevents iron export to circulation, creating a 
negative feedback loop to inhibit further hepcidin release (Nemeth et al. 2004a).  
 
In this study we investigated the effects of quercetin on hepcidin expression, and on 
levels of the iron transporters DMT1 and FPN. Quercetin is a potent iron chelator 
(Afanas'ev et al. 1989) and data from the earlier Caco-2 cells studies suggest that 
quercetin treatment reduces intracellular iron concentration. We therefore 
hypothesized that quercetin should decrease hepcidin and FPN but increase DMT1 
expression. We found that increasing concentrations of quercetin caused a significant 
dose-dependent inhibition of ferroportin gene expression (Figure 4.1). However, 
quercetin treatment induced a dose-dependent increase in hepcidin mRNA. It is 
tempting to speculate that this might be part of an autocrine loop linking hepcidin and 
FPN expression similar to the one observed in human monocytes (Theurl et al. 2008); 
however, it is possible that these are separate quercetin-mediated transcriptional 
events. 
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Interestingly DMT1 expression was significantly down-regulated with as little as 0.1 
µM quercetin (p<0.05; Figure 4.1). This is in contrast to the Caco-2 cells studies 
where DMT1 remained unaltered by even 100 µM quercetin. This is likely due to 
differential expression of DMT1 isoforms (Hubert and Hentze 2002). In addition, the 
decrease in DMT1 argues against quercetin-induced cellular iron deficiency as the 
major mechanism controlling iron metabolism gene expression in HepG2 cells. 
Measurement of ferritin stores and IRP activity would be appropriate to determine the 
extent of changes in cellular iron status following quercetin treatment. 
 
In an attempt to explain how quercetin was inducing hepcidin expression we looked at 
some intermediates in the hepcidin signaling cascade: BMP6 and SMAD4.  Binding 
of the iron-regulated BMP6 to its receptors propagates a signalling cascade that leads 
to phosphorylation of SMAD effector proteins (1/5/8). Once phosphorylated, they 
complex with the common mediator SMAD4 and translocate to the nucleus where 
they modulate transcription of hepcidin (Meynard et al. 2009). The importance of this 
pathway for hepcidin expression has been highlighted in BMP6-deficient mice 
(Meynard et al. 2009) and mice with targeted disruption of SMAD4 (Wang et al. 
2005). 
 
Both BMP6 and SMAD4 levels were higher in the Q100 treatment group but did not 
reach statistical significance. This again argues against an iron-mediated response at 
the mRNA level. However, future studies should also focus on BMP6 protein levels, 
cellular distribution of SMAD4 (nuclear and cytosolic) and the phosphorylation of the 
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receptor-activated SMADs 1,5,8 to determine whether these factors are influenced by 
quercetin in hepatocytes. 
 
4.3.2. Effects of quercetin on cell proliferation and cell viability 
As iron is essential for cell growth, we tested the effect of iron presented in two 
different forms: FAC and haem. FAC did not affect proliferation (0 - 100 µM) but 
haem (50 µM) caused a significant increase of HepG2 cell proliferation (Figure 4.2). 
This suggests that the form of iron presented to cells is an important determinant of 
proliferation. This is consistent with the observation in erythroid cells where 
proliferation was promoted by haem but not FAC (Leimberg et al. 2008). A study 
suggested that the function of iron within a cell is dependent on the form in which it is 
initially presented (Alcantara et al. 1991). They showed that transferrin-bound iron 
was channelled to regulatory functions (indicated by increased PKC-β mRNA) but 
soluble iron in the form of FAC was preferentially channelled to storage sites. 
Therefore, haem could be acting in a similar manner to iron-transferrin and be 
channelled into regulatory functions and this is how it contributes to increased cell 
proliferation whereas FAC is used for storage. To study this proposed mechanism, 
PKC-β mRNA should be measured to see if haem is stimulating this similar to 
transferrin (or some other marker of cell function) and ferritin measured to confirm 
whether FAC is being channelled to storage sites which would explain its lack of 
effect on proliferation. 
 
Quercetin significantly increased proliferation at 10 μM (1.62 ± 0.1) but was reduced 
at 100 μM (0.79 ± 0.1) demonstrating both pro- and anti-proliferative effects 
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depending on the concentration used (Figure 4.3). These findings are supported by the 
work of (Shih et al. 2004) who used rat aortic smooth muscle cells to show that 
quercetin can have both proliferative and anti-proliferative effects, depending on the 
concentration used. Interestingly, 100 μM quercetin returned haem-induced 
proliferation to basal levels showing that quercetin can decrease proliferation as well. 
This is consistent with an iron chelation effect. 
 
Studieshave demonstrated that quercetin can directly inhibit PI3K to affect 
proliferation (Hwang et al. 2009, Weber 2005) therefore we used a PI3K inhibitor to 
see if it would mimic the responses of quercetin if quercetin was truly using the PI3K 
pathway. However the PI3K inhibitor on its own or with FAC/haem had no effect on 
proliferation or cell viability indicating that quercetin is not using this pathway to 
affect these functions in hepatocytes. 
 
Hepcidin did not significantly alter cell proliferation, either when given alone or in 
combination with FAC or haem. Hepcidin is thought to block FPN and increase 
cellular iron (Nemeth et al. 2004b); however, further studies will be required to 
determine whether cellular iron levels altered significantly in the presence of hepcidin 
in our studies.  
 
In contrast to proliferation, FAC appears to have the more significant role on cell 
viability, illustrated by the significant dose-dependent decrease in cell viability with 
increased concentrations of FAC (Figure 4.5). This effect can be attributed to 
increased production of reactive oxygen species resulting in increased iron-dependent 
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cellular damage similar to that observed in other cell lines (Hoepken et al. 2004). 
However this effect was pacified with the addition of quercetin. Although quercetin 
on its own did not affect viability, it was able to bring FAC-viability back to basal 
levels. This is likely an antioxidant effect of quercetin. Along with its iron chelation 
ability, quercetin has been proposed to activate the MAPK pathway leading to 
expression of survival (c-Fos, c-Jun) and defensive genes (phase II detoxifying 
enzymes; glutathione S-transferase, quinone reductase) (Schroeter et al. 2001, Kong et 
al. 2000) reviewed by Williams et al. 2004). Possible activation of these cyto-
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Macrophages are responsible for degrading haemoglobin from senescent erythrocytes 
which allows haem iron to be extracted and released back in tothe circulation for 
further use. The system demonstrates an efficient iron recycling system to maximise iron 
utilisation and minimise iron loss.  
 
Having looked at iron absorption and storage, we next wanted to investigate the 
effects of quercetin on macrophages to see how it would compare with other iron 
compartments. We used Thp1 cells as an in vitro model of human macrophages. Thp1 
cells originate from an acute monocytic leukemia cell line (Tsuchiya et al. 1980). In 
culture, these monocytes float but with the addition of phorbol-12-myristate-13-
acetate, commonly known as PMA, the monocytes differentiate into macrophages and 
adhere to cell culture dishes. They have a doubling rate of 2 - 3 days which makes 
them convenient for laboratory use.  
 
Initially we investigated the effect of quercetin on DMT1 and FPN. TRPML (transient 
receptor potential mucolipin subtype) channels found in intracellular organelles, 
particularly endosomes and lysosomes have been shown to function as iron-permeable 
channels in HeLa and HEK cell lines (Dong et al. 2008). The role of TRPML channels 
in iron metabolism in human macrophages has not yet been investigated. Thus we also 
looked at TRPML1 and TRPML2 (TRPML3 is not permeable to iron) to see how they 
would be affected by quercetin and iron in human Thp1 macrophages. 
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5.2. Effect of quercetin on macrophage iron transporters 
 
Thp1 cells were grown on 12-well plates for 24 hours and were treated with quercetin 
(0, 1, 10 and 100 µM) for a further 24 hours. This was followed by RNA isolation and 
quantitative-PCR to measure changes in mRNA expression. 
 
We found that 1 – 10 µM quercetin had no effect on DMT1, TRPML1 or TRPML2 
expression. However 100 µM quercetin caused a significant down-regulation of all 
these transporters (Figure 5.1).  
 
Quercetin has an opposite effect on FPN in Thp1 cells than it did in Caco-2 and 
HepG2 cells as quercetin caused a significant dose-dependent increase of FPN 





































Figure 5.1 Quercetin increased FPN mRNA expression 
Thp1 cells were treated with quercetin (0, 1, 10, 100 µM) for 24 hours. Changes in mRNA 
expression were measured by q-PCR. Data normalised to housekeeping gene 18S. Data 
analysed by one-way ANOVA and Dunnett’s posthoc compared to untreated control (0). 
Significance:*p<0.05 **p<0.01 ***p<0.001. N=16 (DMT1); 18 (FPN); and 10 (TRPML1/2). 
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5.3. Effect of iron on macrophage iron transporters 
 
As macrophages are responsible for recycling iron, it was of interest to investigate 
whether altered cellular iron concentrations affected the gene expression of these 
putative iron transporters. Cells were treated with 50 μM hemin for 24 hours or left 
untreated. We specifically measured DMT1, Nramp1, TRPML1, TRPML2 and FPN 
by q-PCR. 
 
DMT1 gene expression did not change with increased iron content (0.97 ± 0.37; 
(Figure 5.2). However, all other iron transporters (Nramp1, TRPML1, TRPML2, 
FPN) had significantly reduced mRNA expression with hemin treatment (p<0.05; 









































Figure 5.2 Hemin significantly reduces gene expression of most iron transporters 
Thp1 cells were treated with hemin (50 µM) for 24 hours and mRNA expression measured by 
q-PCR. Data normalised to housekeeping 18S. Data analysed by t-test compared to untreated 
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5.4. Ferroportin 5’UTR promoter 
 
Both variants of the FPN prompter (FPN1A and FPN1B) were transiently transfected 
into Thp1 cells. We measured transfection efficiency to be sure that the promoter had 
been correctly inserted and was driving firefly luciferase expression. FPN1A caused 
over a 7-fold increase in luciferase activity compared to the empty, promoter-less 
control vector (p<0.01; Figure 5.3).  FPN1B caused a significant 5.5-fold increase 











Figure 5.3 Transfection efficiencies of FPN1A/1B as compared to empty PGL4 vector 
Thp1cells were incubated for 24 hours after transfection and harvested for the Luciferase 
assay. Data analysed by t-test compared to empty pGL4 vector. Significance: **p<0.01 **** 
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5.4.1. Effect of quercetin and iron on FPN1A/FPN1B promoters 
To examine the responses of both promoter constructs to iron loading, Thp1 cells were 
transiently transfected with the FPN1A or FPN1B plasmid for 24 hours. Media was 
then replaced and cells were treated with quercetin (10 µM), hemin (50 µM) or 
quercetin and hemin combined for 24 hours.  
 
Quercetin caused significant induction of both FPN promoter transcripts (FPN1A 1.56 
± 0.11 p<0.05; FPN1B 1.36 ± 0.08 p<0.01) (Figure 5.4). Iron loading with the 









Figure 5.4 Quercetin significantly increased FPN1A/1B promoter activities 
Thp1 cells were incubated 24 hours after transfection and treated with quercetin (10 µM) 
and/or hemin (50 µM) for further 24 hours. Data was normalised to untreated control (FPN1A 
or FPN1B alone). Data analysed by one-way ANOVA and Dunnett’s post-hoc test. 
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5.4.2. Effect of Epo on FPN1A/1B promoters 
As Epo has been shown to stimulate the activity of FPN1B but not FPN1A in Caco-2 
cell, we investigated whether this differential stimulatory effect of Epo would also 
occur in human macrophages. Thp1 cells were treated with recombinant 
erythropoietin (Epo) (1 U/ml) and in combination with quercetin (10 µM) for 24 
hours. 
 
Epo did not induce significant activity of either promoter, when treated alone or with 








Figure 5.5 Epo has no effect on ferroportin promoters 
Thp1cells were incubated 24 hours after transfection and treated with, Epo (1U/ml) or 
together with quercetin (10 µM) for another 24 hours. Data was normalised to untreated 
control (either FPN1A or FPN1B alone). Data analysed by one-way ANOVA and Dunnett’s 
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5.4.3. Effect of HIF1α and HIF2α inhibitors on FPN1A/1B promoters 
We examined the effect of HIFs on ferroportin promoters by using HIF1α (20 µM) 
inhibitor and HIF2α (10 µM) inhibitor. The HIF inhibitors were also co-incubated 
with quercetin (10 µM). 
 
We found that neither HIF1α inhibitor nor HIF2α inhibitor had any significant effect 
on the FPN promoters (Figure 5.6). Co-incubation with quercetin caused a slight 


































Figure 5.6 HIF1α and HIF2α inhibitors have no effect on FPN1A/FPN1B promoter 
activities 
Thp1 cells were treated with HIF1α inhibitor (20 µM) or HIF2α inhibitor (10 µM) either alone 
or together with quercetin (10 µM) for 24 hours. Data was normalised to untreated control 
(FPN1A alone without any treatment). Data analysed by one-way ANOVA and Dunnett’s 








































































































































































































DMT1, Nramp1, TRPML1 and TRPML2 are divalent metal transporters expressed in 
the phagolysosomal membranes of macrophages and are suggested to be involved in 
recycling iron from senescent erythrocytes and trafficking iron through the 
macrophage (Gunshin et al. 1997, Kuhn et al. 1999, Dong et al. 2008, Soe-Lin et al. 
2008). Ferroportin (FPN) is the only known cellular iron exporter. These results 
demonstrated that most, but not all of these THP1 iron transporters are at least partly 
regulated by intracellular iron concentrations. 
 
This section of the study was designed to investigate whether changes in cellular iron 
concentration altered the expression of THP1 macrophage iron transporters. It was 
predicted that increasing cellular iron with the addition of hemin (50μM) would 
decrease expression of iron transporters so as to stop iron overload. Conversely, a 
decrease of iron by the iron chelator quercetin would increase the gene expression of 
these transporters. As predicted, hemin caused a significant reduction in the mRNA 
expression of Nramp1, TRPML1, TRPML2 and FPN (Figure 5.2).  
 
Nramp1 (Natural resistance-associated macrophage protein 1) is expressed in the 
membrane fraction of macrophages (Vidal et al. 1996) with highest expression being 
in circulating macrophages and monocytes (Cellier et al. 1994). As a divalent 




 as well as Fe
2+
 (Kuhn et al. 1999) 
however there is controversy as to the direction of iron transport with no general 
consensus being reached. On the one hand, Nramp1 has been reported to transport 
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iron into phago-lysosomes (Kuhn et al. 1999) but on the other, studies suggest 
Nramp1 is involved in iron efflux out of phago-lysosomes and even out of cells (Biggs 
et al. 2001, Mulero et al. 2002). Our results show an inverse relationship of decreased 
Nramp1 expression with increased iron concentration which is more consistent with a 
role of Nramp1 as an efflux protein in the phago-lysosmal membrane involved in 
macrophage iron trafficking. The inverse correlation found contradicts others who 
have found a parallel relationship between Nramp1 protein expression and iron levels 
in macrophages (Atkinson and Barton 1999, Baker et al. 2000, Soe-Lin et al. 2008) 
but these studies often use a different strain of macrophage such as murine RAW264.7 
or J774 which may account for the differences. These cell lines originate from 
Nramp1
D169
 mice and do not produce mature Nramp1 protein (Vidal et al. 1996). 
Transfection with exogenous Nramp1 as in Soe-Lin et al (2008) (RAW264.7 
transfected with Nramp1
G169
) is unlikely to produce the same effects as endogenous 
Nramp1 in Thp1 macrophages. 
 
Dong et al. (2008) recently demonstrated that transient receptor potential mucolipin 1 
(TRPML1) is ubiquitously expressed and encodes for an iron release channel found in 
the late endosome and lysosome. Lysosomes are components of the endocytic 
pathway that digest the cellular material delivered to autophagosomes during cell 
renewal and death (reviewed in (Luzio et al. 2005)). The role of the TRPML channels 
has not yet been looked at in human macrophages.  
 
We found that both TRPML1 and TRPML2 were expressed in macrophages and their 
expression was regulated in a similar manner by being significantly reduced with 
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hemin treatment suggesting a similar type of role to Nramp1 of iron efflux. TRPML1-
deficient fibroblast cells exhibit lysosomal iron overload as well as cytosolic iron 
deficiency which is consistent with a role of TRPML1 in endolysosomal iron release 
(Dong et al. 2008). However with evidence that TRPML1 is also permeable to Ca
2+
 
(LaPlante et al. 2004) this makes it unlikely that TRPML1 is solely dedicated to iron 
metabolism. 
 
DMT1 was the only transporter that was not altered by hemin treatment. One possible 
reason for this is that hemin presents iron in a form that is inaccessible to DMT1. The 
use of hemin for cellular iron loading is based on the assumption that following 
erythrophagocytosis, or hemin treatment, haem is catabolised within the 
phagolysosome by haem oxygenase. It has recently been shown that DMT1 may not 
be recruited to the erythrophagosomal membrane (Delaby et al. 2012) suggesting that 
DMT1 may be involved in iron acquisition in macrophages via the transferrin-
transferrin receptor cycle rather than recycling of haem iron from haemoglobin. In 
addition the primers used in this study to amplify DMT1 are common to all DMT1 
isoforms. The use of isoform-specific primer sets would allow us to explore more 
fully the effect of iron on DMT1 expression.  
 
Our results showed that in response to quercetin (1 – 100 µM), DMT1 and TRPML1/2 
expression only altered significantly with 100 uM quercetin (Figure 5.1). However, at 
this concentration quercetin could be affecting cell viability (as observed in HepG2 
cells). In future, a Trypan blue exclusion test or a cell viability assay should be 
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performed to see if this is the underlying reason for the dramatic decrease in 
expression.  
 
In contrast to the other transporters investigated, quercetin caused a significant dose-
dependent increase in FPN expression. This was surprising as quercetin decreased 
FPN expression in both Caco-2 and HepG2 cell lines. We therefore transfected Thp1 
macrophages with 5’FPN promoter constructs to examine whether quercetin was 
having any effect on promoter activity in Thp1 cells. We found that quercetin (10 µM) 
did indeed significantly induce both FPN1A and 1B promoter activities, whereas 
hemin had no effect. In contrast, in Caco-2 cell line quercetin had no effect on FPN1A 
or 1B. This data strongly implies that quercetin stimulates the FPN promoter to 
increase FPN expression independent of iron levels and that this effect is specific only 
to macrophages. This demonstrates the cell-specific effects of quercetin and that FPN 
is differentially regulated dependent on cell/tissue. Differential effects on FPN 
expression in enterocytes and macrophages have been previously reported in response 
to hepcidin (Chaston et al. 2008, Chung et al. 2009). These studies showed that 
hepcidin rapidly decreased FPN expression in mouse splenic macrophages and Thp1 
cells but had no effect on mouse duodenal enterocyte or Caco-2 cell FPN.  
 
Quercetin may upregulate FPN in order to maintain the demands of erythropoiesis. 
However when we looked at Epo stimulation of FPN, the stimulatory effect on FPN 
promoter observed in Caco-2 cells was not seen in Thp1. Similarly, inhibiting the 
hypoxia inducible factors, HIF1α and HIF2α, which are also activated by iron 
deficiency and erythroid requirement for iron, had no effect on FPN promoter activity.  
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It is possible that quercetin acts by stimulating Nrf2 activity in macrophages. Nrf2, 
through binding to antioxidant responsive elements in the 5’promoter has been shown 
to increase FPN expression in macrophages (Marro et al 2010). Future studies should 
explore this pathway in more detail. 
 
Our work in the Thp1 cell linepresents exciting new possibilities that quercetin 
regulates macrophage iron metabolism. Macrophages are the major contributor to 
body iron turnover, recycling approximately 25 mg iron/day from red blood cells. 
Factors which can regulate this turnover might be important therapeutically for 
treating a number of iron-related disorders. We have shown that TRPML1 and 
TRPML2 expressed in human THP1 macrophages have an inverse relationship with 
cellular iron concentration. These iron transporters as well as Nramp1 and FPN, but 
not DMT1, are regulated by iron. FPN shows an additional regulation by quercetin 
which uses the 5’UTR promoter to increase FPN expression. Whether the stimulatory 
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6.1. General conclusion 
 
Systemic iron homeostasis requires a meticulous coordination of intestinal iron 
absorption, efficient recycling of iron from senescent erythrocytes and controlled 
storage of iron in hepatocytes and macrophages (Andrews 2008). This thesis 
investigated the regulatory effects of one of the most dominant dietary polyphenols, 
quercetin, on all three aspects of iron metabolism and investigated its mechanism of 
action. 
 
In Caco-2 cells we showed that quercetin significantly down-regulated FPN gene and 
protein expression. Through miRNA array screening and validation studies, we have 
identified the miRNA hsa-miR-17-3p as a novel candidate for quercetin-induced FPN 
regulation. Previous work in the field has shown that miRNAs can regulate gene 
expression of iron transporters in other cell types such as miR-Let-7d for DMT1(-IRE) 
in erythroid cells (Andolfo et al. 2010) and miR-485-3p for FPN in hepatocyte and 
erythroid cells (Sangokoya et al. 2013). Computational analyses suggest that miRNAs 
may regulate up to 30% of human protein-coding genes (Lewis et al. 2005) although  
only a very small number of target genes have actually been experimentally 
confirmed. 
 
Mechanistically, miRNAs repress translation and/or mediate RNA degradation (Wu et 
al. 2006).  Therefore activation of miR-17-3p by quercetin may regulate FPN by 
causing mRNA degradation and/or preventing RNA translation explaining low levels 
of both FPN gene and protein with increased quercetin treatment. miRNAs tend to be 
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cell-specific (Castoldi et al. 2011, Andolfo et al. 2010) and interestingly quercetin 
increased FPN expression in  macrophages rather than decrease as it did in Caco-2 and 
HepG2, suggesting that quercetin is using different regulatory mechanisms. This 
highlights that FPN is differentially regulated dependent on tissue type and is 
supported by in vivo work showing that FPN in macrophages and enterocytes 
responds differently to hepcidin challenge (Chaston et al. 2008, Knutson et al. 2005, 
Chung et al. 2009). 
 
Quercetin treatment on HepG2 cells showed a stimulation of hepcidin mRNA 
expression. As the site of hepcidin synthesis, this increased production could provide 
an additional means of inhibiting intestinal iron absorption via FPN degradation. 
Quercetin also exhibited both pro- and anti- proliferative/apoptotic effects; this was 
conditional on the type of iron used (Leimberg et al. 2008, Alcantara et al. 1991) and 
concentration of quercetin used (Shih et al. 2004, Granado-Serrano et al. 2006). 
 
Taken together, these results show various mechanisms at play and emphasise the 
potential benefits of quercetin on iron-related disorders (Figure 6.1). In iron overload 
situations, inhibition of intestinal FPN by quercetin would limit dietary absorption of 
iron. Increased hepatic hepcidin production would further help to limit iron uptake 
(Nemeth et al. 2004b). However as quercetin is shown to stimulate Thp1 FPN, 
quercetin may counteract the effects of increased hepcidin specifically in macrophages 
to ensure that a constant and consistent iron recycling system is in place to maintain 
iron supply for erythropoiesis. This would be particularly useful in conditions 
associated with anaemia of chronic disease where macrophages have high iron 
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retention but a lack of iron export results in reduced erythropoiesis (Weinstein et al. 
2002). Quercetin may also have positive patho-physiological effects. In iron overload 
diseases such as hereditary haemochromatosis, iron accumulation often occurs in the 
liver (Nancy C. Andrews 1999). Our results show that FAC decreased hepatocyte cell 
viability, which in vivo could lead to fibrosis; whereas exposure to haem increased 
proliferation which could be pro-tumourogenic. Addition of quercetin was able to 
counteract both of these effects highlighting the potential beneficial effects of 



















































Figure 6.1 Proposed working model for the regulatory actions of quercetin on iron 
metabolism 
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6.2. Further study 
 
This work has investigated, discovered and proposed mechanisms of quercetin action 
on iron metabolism in well established cell lines. Similar studies need to be carried out 
in vivo in animal models to confirm these effects and should be followed by human 
intervention studies to determine any potential benefits for groups at risk of 
developing iron metabolism-related disorders.  
 
Having looked at 5’FPN promoters as a means of FPN regulation, we did not find any 
quercetin interaction. However, the promoter tested was only a small fragment 
(895/1050 bp) and it could be that quercetin interacts with FPN further upstream 
therefore further work exploring the whole 5’UTR sequence is warranted for possible 
sites of quercetin regulation. 
 
We showed that recombinant erythropoietin (Epo) stimulation of FPN gene expression 
could be blocked by quercetin in Caco-2 cells, suggesting that quercetin was affecting 
FPN expression by an Epo-stimulatory pathway. Focusing on the PI3K pathway we 
found that quercetin and LY294002 (a PI3K inhibitor) had similar effects in support 
of this hypothesis. However phospho-Akt, a downstream target of PI3K, is also a 
protein of interest as its phosphorylation is increased by Epo. Western blotting should 
be performed to see whether both quercetin and LY294002 inhibit phosphorylation of 
Akt to confirm they are working by the same pathway. Furthermore, in addition to 
PI3K/Akt pathway, phosphorylated Epo-R activates multiple downstream kinase 
pathways including JAK2 and MAPK (Marzo et al. 2008) and it might be that 
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quercetin is affecting these (Kong et al. 2000). Specific kinase inhibitors should be 
used in cell models to examine their effects on FPN and then compared to Epo and 
quercetin responses as indication of shared pathways for FPN regulation. 
 
This study noted that hsa-miR-17-3p was upregulated by quercetin and may be 
responsible for FPN downregulation in intestinal cells, thus a hsa-miR-17-3p mimetic 
should be used to block this pathway in the Caco-2 model to see if FPN mRNA down-
regulation is also inhibited. In mouse models, this miRNA, along with other miRNAs 
possibly involved in regulation of iron metabolism genes, should be validated by q-
PCR and similar experiments with mimetics/inhibitors should be performed. 
 
Several mouse models of iron-overload have been developed over the years including 
Hfe knockouts (Hfe −/− ) (Fleming et al. 2001), β-thalassaemic mice (Raja et al. 1994) 
and hepcidin knockout mice (Hepc1–/–) (Nicolas et al. 2001, Lesbordes-Brion et al. 
2006). Strategic use of these mouse models in dietary feeding studies giving quercetin 
at a range of nutritionally acceptable doses (0.006 - 0.06% (w/w) corresponding to an 
equivalent human intake of 30 - 300 mg/day) (Milenkovic et al. 2012) would allow an 
assessment of how dietary polyphenols might interact with iron sensing, storage, 
transport and recycling. These studies may  identify novel pathways that could be 
exploited for future development of therapies to treat disorders of iron homeostasis.  
 
The ultimate goal is to explore the therapeutic effects of quercetin and trial it as an 
iron chelator and modifier of iron absorption in human studies, focusing on patients 
with iron-overload diseases. As a natural occurring compound in the diet, effective 
doses of quercetin should be well-tolerated and could provide an adjunct to current 
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therapies. The effect of quercetin on miRNAs also opens up the possibility of miRNA 
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